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Antiretroviral therapy (ART) requires lifelong daily dosing to suppress viral 
replication, restore or maintain immune function and improve quality of life. As an 
alternative, long-acting (LA) antiretrovirals (ARVs) aim to deliver therapeutic drug 
concentrations over an extended period, ultimately requiring monthly or even more 
extended dosing intervals. Specifically, the success of recent clinical trials examining LA 
cabotegravir and rilpivirine (CAB and RPV LA) highlight the advent of these novel HIV-1 
therapeutics. Further optimization of LA dosage forms are required and rests upon 
improving dosing frequency, injection volumes and tissue distribution to viral 
compartments. To this end, we report the synthesis of a library of RPV prodrugs 
specifically designed to provide sustained drug plasma concentrations and enhance 
tissue distribution. Lead prodrug candidate M3RPV was nanoformulated to develop a 
stable LA injectable dosage form (NM3RPV). Specifically, NM3RPV provided RPV 
plasma concentrations above the PA-IC90 for 25 weeks, while concurrently generating a 
substantial tissue depot after in single injection in BALB/cJ mice. Furthermore, NM3RPV 
provided 13 and 26-fold increases in t1/2 and MRT compared with NRPV respectively. 
Therefore, these results provide proof-of-concept nanoformulated RPV prodrugs can 
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effectively extend the apparent half-life and improve tissue distribution compared to 
nanoformulated RPV (NRPV), warranting further investigation and optimization
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CHAPTER	  1-­‐	  INTRODUCTION	  
 
1.1 Global Impact of HIV/AIDS 	  
Since the beginning of the HIV/AIDS epidemic in early 1980s, 77.3 million people 
have become infected with HIV, with 35.4 million dying from AIDS-related illnesses 
during this timeframe.1 Antiretroviral therapy (ART) has revolutionized patient care for 
HIV-1 infected individuals providing a life span approaching that of the general 
population.2,3 In particular, between 2000 and 2017, coinciding with the advent of ART, 
new HIV infections and HIV-related deaths have decreased by 36 and 38% 
respectively.4 Notwithstanding, as of 2017 only 59% of HIV-infected adults were 
receiving ART.1 Furthermore, HIV is still endemic in eastern and southern Africa where 
an estimated 19.6 million people are currently living with HIV, a substantial 53% of the 
global disease burden.1 Therefore future treatment strategies must focus on delivering 
ART is a more efficient, discrete, and reliable manner to increase drug access and 
effective use. 
1.2 HIV-1 Pathobiology 	  
HIV-1 infection requires viral entry into its target cells (CD4+ T-cells; monocytes; 
dendritic cells and macrophages). Cellular entry is facilitated by viral envelope (env) 
glycoprotein 120 (gp120) and glycoprotein 41 (gp41). Specifically, gp120 binds to CD4 
on the host cell surface.5 This interaction facilitates a conformational change in gp120, 
whereby the newly exposed V3 loop binds its co-receptor target (CCR5 or CXCR4).6 Co-
receptor binding exposes HIV-1gp41 enabling interaction between viral and host cell 
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membranes, ultimately generating membrane fusion and exposure of viral RNA to the 
cytoplasm.7 HIV-1 is a retrovirus, thus after cellular entry conversion of its single 
stranded RNA genome into double stranded circular DNA is required and accomplished 
by reverse transcriptase (RT).8 Viral DNA is subsequently transported into the nucleus 
as a pre-integration complex (PIC) and integrated into the host cell genome with the help 
of the virally encoded integrase enzyme.9 Integrated proviral DNA can remain latent or 
be expressed at low levels using host cell machinery. Expression of HIV-1 DNA in turn 
produces viral proteins such as trans-activator of transcription (Tat) which stimulate 
more efficient HIV-1 transcription.10 Furthermore, HIV-1 gag polyprotein facilitates the 
assembly, budding, and with assistance from HIV-1 protease, the production of 
infectious virions destined to infect more host cells.11 (Figure 1.5.1)12 
 In the human host, HIV-1 infection is a major threat to immunity. Patients typically 
experience a severe depletion of CD4+ CCR5+ T-cells in the gut with the onset of 
infection.13 Clinical manifestations of early infection often present as flu-like symptoms, 
but as the disease progresses and plasma viremia reach their set point, patients can 
become asymptomatic for an extended period of time. Within the host body, destruction 
of the CD4+ T cell population is accompanied by robust immune activation. If a patient is 
left untreated, a depleted immune system would eventually succumb to opportunistic 
infections. Therefore, means to monitor HIV-1 plasma viral load and CD4+ T cell counts 
is essential.  ART is essential not only prolong the life span of infected individuals but in 
reducing the propagation and further spread of infection to other human hosts. 
1.3 ART 	  
Between the first clinical observations of HIV (1981) and clinical trials for 
zidovudine (AZT; 1987), clinicians were relegated to the treatment of opportunistic 
infections associated with HIV/AIDS.14,15 It became apparent that combination ART was 
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   3	  
necessary to slow disease progression, avoid development of resistance, and reduce 
morbidity and mortality due to opportunistic infections.16-19 As the basic understanding of 
HIV-1 and its viral life cycle improved, more targets were identified for medicinal 
chemists to develop novel antiretroviral compounds. Thus, protease inhibitors (PIs) were 
discovered in 1995 (saquinavir), while the first non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) were approved 1996 (nevirapine).20,21 Quickly new classes of 
compounds emerged and attained FDA approval, such as fusion inhibitors (enfuvirtide; 
2003), entry inhibitors (maraviroc; 2007), and integrase inhibitors (raltegravir; 2007).22-24 
Patient quality of life continued to improve as ART more readily managed HIV-1 
infection, although a significant number of pills and multiple daily dosing schedules 
remained a requirement. Further advances included the development of single tablets 
containing multiple drug classes, first exemplified by efavirenz (EFV), emtricitabine 
(FTC), and tenofovir disoproxil fumarate (TDF).25 Strict adherence to modern ART 
therapy reduces plasma viral loads below the limit of detection, offers comparable life 
spans to the general population, and provides a 96% reduction in sexual transmission 
between HIV-1 serodiscordant couples.2,26 General guidelines for current ART suggest 
the use of two nucleoside reverse transcriptase inhibitors (NRTIs) administered with an 
nonnucleoside reverse transcriptase inhibitor (NNRTI), integrase inhibitor (INSTI) or a 
protease inhibitor (PI), with a booster).27 Common ART combinations include bictegravir-
tenofovir alafenamide-emtricitabine (biktarvy) and dolutegravir-abacavir-lamivudine 
(triumeq). Furthermore, new potent compounds continue to be developed (cabotegravir, 
CAB), as well as the repurposing of existing ARVs for monthly delivery by intramuscular 
injection (rilpivirine, RPV and CAB LA).28 Certainly, ART has been one of most 
significant achievements in modern medicine, enabling millions of infected individuals to 
live with HIV-1 and have productive lives. Specifically, between 2000 and 2017 an 
estimated 11.4 million lives were saved due to ART.4 Notwithstanding, significant 
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progress is still required considering only 75% of infected individuals know their status, 
of which 79% are accessing ART, and 81% which are virally suppressed.1 Therefore, the 
90-90-90 initiative has been implemented to strive for 90% of all HIV infected individuals 
to be aware of their status, receive ART treatment, and ultimately achieve viral 
suppression by 2020.29 Thus, next generation ART will focus on improving drug access 
and utilization in underserved communities, as well as improving the compliance and 
ease of use for individuals already on ART. 
1.3.1 RPV 	  
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) bind to a hydrophobic 
binding pocket near the reverse transcriptase (RT) catalytic site, thus acting as allosteric 
inhibitors. Rilpivirine is a highly active diarylpyrimidine NNRTI with sub-nanomolar 
activity against wild-type virus (0.73 nM).30 RPV is more active against a broad range of 
viral mutants, differentiating it from other NNRTIs such as Nevirapine (NVP) and 
Efavirenz (EFV).31 The broad-spectrum inhibitory nature of RPV across NNRTI resistant 
strains is likely due to its flexibility within the RT binding pocket.31 Furthermore, RPV is 
associated with less reported adverse events than NVP and EFV, which have been 
observed to generate hepatotoxic and neuropsychiatric side effects respectively.32,33 
RPV is slowly metabolized by liver hepatocytes, thus its observed slow metabolic 
clearance results in a long half-life (~45 hours), allowing for once-daily dosing.31,34 
Currently RPV is indicated for once-daily oral delivery (25 mg) in adults with HIV-1 RNA 
≤ 100,000 copies/mL in treatment naïve patients in two fixed-dose combinations, 
Complera (RPV-TFV-FTC) and Odefsey (RPV-TAF-FTC).35 Moreover, the first two-drug 
fixed dose once-daily oral regimen (Juluca) was approved for treatment experienced 
patients exhibiting viral suppression (HIV-1 RNA < 50 copies/mL) consisting of DTG (50 
mg) and RPV (25 mg).35,36 Furthermore, RPV has been investigated as a long-acting 
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injectable formulation for monthly delivery.37,38 Particularly, its combination of high 
potency and low solubility selected RPV for LA formulation development securing its 
status as highly important compound for the next generation of ART.39  
1.3.2 Maraviroc (MVC) 	  
MVC is a small molecule allosteric antagonist of CCR5 and represents the first 
and only FDA approved HIV-1 entry inhibitor. Specifically, MVC bound to CCR5 
generates a conformational change whereby efficient interaction between HIV-1gp120 
and CCR5 is no longer possible. Entry inhibitors such as MVC have been attractive drug 
targets due to the cure of the “Berlin patient”, as well as observations of delayed disease 
progression in individuals heterozygous for the Δ32 CCR5 deletion mutation.40,41 
Furthermore, its significant distribution to vaginal and rectal tissue, as well as semen has 
garnered MVC interest in pre-exposure prophylaxis (PrEP).42,43 MVC is only effective 
against R5 tropic HIV-1 stains, thus requires a tropism test before use and is currently 
recommended for used in treatment experienced patients that have experienced 
previous virologic failure. 
1.4 Clinical History of LA Therapy 	  
LA dosage forms are available for indications ranging from contraceptives to 
antipsychotics.44-46 In particular, LA contraceptives are available as implants or injectable 
formulations. For example, Depo-Provera, comprised of medroxyprogesterone acetate 
microcrystals, requires quarterly injections eliminating the need for daily pills.46 
Furthermore, reversible methods of LA contraception, such as intrauterine devices 
(IUDs) and subdermal hormonal implants continue to permeate the market.47 
Specifically, levonorgestrel-releasing IUDs such as Liletta and Mirena are effective for 3 
and 5 years respectively. Furthermore, subdermal implants, such as the esonogestrel-
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releasing Nexplanon is highly efficient during its 3-year effectiveness window. In 
addition, LA antipsychotics utilize multiple dosage forms such as oil depots, aqueous 
suspensions of prodrugs or hydrophobic salts, and/or polymeric microparticles to 
increase patient compliance and reduce adverse neurological side effects.45 Recently, 
Invega Trinza, a microsuspension of the prodrug paliperidone palmitate received 
approval for quarterly dosing for the treatment of schizophrenia.48 Therefore, clinically 
approved LA dosage forms for birth control and schizophrenia provide important 
examples of extended release delivery; technologies which will need optimization to 
meet the unique needs and requirements of HIV-1 treatment.  
1.5 LA HIV-1 Therapy 	  
ART compounds were originally synthesized and designed for oral delivery. 
Therefore drug physicochemical properties were tailored to achieve high bioavailability 
by providing stability in the gastrointestinal tract (GI), adequate absorption into the blood 
stream, and limited first-pass metabolism.49 Thus a balance of low molecular weight, 
suitable aqueous solubility, moderate lipophilicity, and low hydrogen bonding capacity 
define solid drug candidates for oral delivery. Therefore, translating existing ARV 
compounds into LA therapeutics requires careful considerations and ultimately 
determines their formulations design (Implant; Injectable formulation; Prodrug). 
1.6 LA Parenterals (LAP)  	  
Translating LA injectable formulations used for antipsychotic and/or 
contraceptives into LA treatments for HIV-1 requires careful examination of drug 
solubility, potency, and half-life. For example, antipsychotic paliperidone and 
contraceptive medroxyprogesterone acetate require just 3-12 and 2.5-10 mg daily oral 
dosages respectively.39 In comparison, some ARVs such as 3TC (300 mg/day), EFV 
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   7	  
(600 mg/day) and RAL (800 mg/day) require significantly higher doses.50 Therefore, in 
order to facilitate formulation, limit injection volumes, and deliver efficacious 
concentrations of drug, injectable HIV-1 treatments have focused on the development on 
hydrophobic compounds such as CAB and RPV that require daily oral doses of (10-60 
mg) and 25 mg respectively.  
 RPV-LA is an investigational LA formulation under development by Janssen. 
Early proof of concept work focused on optimizing drug form (RPV-free base or RPV-
HCL), nanoparticle size (200, 400, 800 nm), surfactant selection (P338, d-alpha-
tocopheryl polyethylene glycol 100 succinate; TPGS), and route of administration (IM; 
subcutaneous; SC)37 Dose response (300, 600, 1200 mg) pharmacokinetic studies in 
HIV-1 seronegative patients established RPV-LA as well tolerated and able to produce 
clinically relevant RPV plasma concentration for an extended period of time.38  
 Cabotegravir, an investigational integrase inhibitor and structural analogue of 
DTG is currently in clinical development as both an oral therapy and LA injectable 
formulation (CAB-LA).51 CAB-LA is produced by wet-milling using polysorbate 20 and 
polyethylene glycol 3350 as stabilizers to generate 200 nm nanocrystals.51 Phase I 
clinical trials demonstrated CAB-LA was well tolerated and provided plasma CAB 
concentrations above its IC90 for 16 weeks in healthy patients, thereby offering proof of 
concept for its potential application in HIV-1 treatment.52 Furthermore, rhesus macaque 
studies determined the effectiveness of CAB-LA protection against viral challenge 
though multiple routes of infection.53-55 
Ultimately, proof-of-concept studies with RPV-LA and CAB-LA culminated in their 
combination to determine efficacy in multiple clinical trials for HIV-1 maintenance 
therapy. Specifically, the LA Antiretroviral Treatment Enabling (LATTE-2) trial 
demonstrated CAB-LA (400; 600 mg) and RPV-LA (600; 900 mg) in combination every 4 
or 8 weeks was non-inferior to daily oral therapy (CAB-ABC-3TC; 30-600-300 
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   8	  
mg)(Figure 1.5.2).28 These results were reinforced by successful phase 3 clinical trials 
(ATLAS and FLAIR) and positive patient feedback, thereby generating strong support for 
the future of LA ARVs.56,57 
1.7 HIV-1 LA Implantable Formulations and Technologies 	  
Implantable technologies provide sustained drug concentrations for an extended 
period of time and also provide a platform to integrate more hydrophilic ARVs. In 
addition, sub-Saharan Africa, which bears the largest global burden of HIV-1, has 
observed increased use of implants for contraception, thereby setting precedent for their 
use in a resource-limited setting.58,59 
To this end, a sustained release implantable formulation of TAF was developed 
using a PVA-coated silicone cylinder loaded with TAF powder.60 In particular, the TAF 
implant delivered detectable concentrations of TAF, TFV, as well as, the 
pharmacologically active TFV-diphosphate (TFV-DP) over a period of 40 days in beagle 
dogs.60 Moreover, TFV-DP was detected at concentrations 30 times higher than 
observed in HIV-1 human PrEP studies, lending credence to its importance as a 
continued research objective.60  
Furthermore, biodegradable implants consisting of poly(lactic-co-glycolic acid) 
(PLGA), N-methyl-2-pyrrolidone (NMP), and integrase inhibitor dolutegravir generated 
detectable DTG concentrations 9 months after insertion.61 Such implants require 
subcutaneous injection for insertion and are inspired by Eligard, which uses Atrigel 
technology and is commercially available to treat prostate cancer.62 Biodegradable 
implants delivered by subcutaneous injection have substantial advantage of other 
implants, which require surgical insertion and removal. Therefore the report of a 
biodegradable implant capable supplying sustained ARV concentration has tremendous 
potential, especially in the context of HIV-1 PrEP.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   9	  
MK-8591 is an investigational nucleoside reverse transcriptase translocation 
inhibitor (NRTTI) currently under development by Merck.63 Research detailing MK-8591 
incorporation into a LA implantable formulation consisting of biodegradable polymers 
polylactic acid (PLA), polycaprolactone (PCL), or polyethylene vinyl acetate (EVA) has 
recently been reported.64 Specifically, when administered to rhesus macaques, MK-8591 
PCL implants provided detectable drug concentrations up to 6 months.  
Moreover, phase III clinical trials investigating the efficacy of dapivirine vaginal 
rings were recently reported.65 Specifically, dapivirine rings administered monthly, 
generated a 27% reduction in HIV-1 incidence compared with placebo.65 Interestingly, 
the efficacy of treatment differed amongst age groups where 65% efficacy was observed 
in patients over the age of 25, but just 10% in participants under 25.65 These results 
underscore the importance of adherence for PrEP efficacy, even in the context of 
sustained release dosage forms.  
1.8 HIV-1 LASER-ART Formulations 	  
In short order, HIV-1 infected patients will have options that rest outside standard 
oral therapy. Current iterations of LA injectable formulations and/or implants are limited 
by large injection volumes, injection site reactions (ISR), dosing frequency, and lack of 
tissue reservoir penetrance. To address these issues and generate the next generation 
of LA HIV therapeutics, long-acting slow effective release antiretroviral therapy (LASER-
ART) was developed (Figure 1.5.3)66,67. Incorporating rationally designed hydrophobic 
and lipophilic prodrugs of existing ARVs into a LAP; a number of limitations can be 
subverted or improved.  
Briefly, prodrugs are considered bioreversible chemical modifications of an active 
compound.68 Therefore, chemical or enzymatic cleavage is required in vivo to yield the 
active molecule. Reversible chemical modification provides flexibility to add chemical 
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moieties specifically designed to alter a compounds hydrophobicity, lipophilicity, and/or 
membrane penetrance without negatively effecting the drug’s action. Thus, in the context 
of HIV-1, prodrugs can be designed to improve upon suboptimal characteristics of 
existing ARVs, thereby facilitating their transition into LA dosage forms. Prodrug 
synthesis is dependent on the presence of reactive functional groups such as hydroxyl, 
amine, carboxylic, or phosphate moieties, which can generate a range of bonds 
including ester, amide, carbamates, ethers, and phosphates.69 Furthermore, bond 
stability prominently affects systemic release kinetics; therefore, the design of prodrugs 
requires knowledge of the biological system and desired pharmacological outcome. 
Specifically in the context of LA HIV-1 therapeutics, tailoring the release kinetics to 
generate efficacious plasma concentrations and sufficient tissue penetrance is essential. 
 To this end, long acting slow effective release ART (LASER ART) preparations of 
integrase inhibitors DTG and CAB were recently reported.70,71 Specifically, a myristoyl 
ester prodrug of DTG (MDTG) was synthesized and subsequently nanoformulated 
(NMDTG) using poloxamer 407 (P407).70 Murine pharmacokinetic studies generated 
DTG plasma concentrations above the PA-IC90 for 8 weeks after a single IM injection. 
Additionally, DTG concentrations in tissue (spleen, lymph node, GALT, liver, lung, 
kidney) were significantly higher in groups treated with NMDTG compared to those 
treated with nanoformulated DTG (NDTG). Furthermore, NMDTG administered in rhesus 
macaques observed DTG concentrations above the PA-IC90 for 35 days following a 
single 45 mg/kg IM injection.72 Of utmost importance, treatment with NMDTG generated 
significant protection against HIV-1ADA in a CD34+ humanized mouse model, 
underscoring the long-term efficacy of LASER-ART. 
 Furthermore, a myristoylated prodrug of CAB (MCAB) afforded further proof of 
concept LASER-ART can improve the apparent half-life and tissue distributions better 
than LA formulations of unmodified ARVs. Specifically, nanoformulated MCAB (NMCAB) 
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   11	  
was compared against CAB-LA, which is currently in phase III clinical trials.71 NMCAB 
generated a 4x increase in terminal CAB apparent half-life compared with CAB-LA in 
BALB/cJ mice. PK improvements were paired with significant biodistribution 
enhancements. Furthermore, rhesus macaques administered with NMCAB (45 mg/kg-
CAB eq.) displayed CAB plasma concentrations above the PA-IC90 for 12 weeks.73 
 LA injectable formulations require hydrophobic ARVs, which are incorporated into 
solid drug nanosuspensions. Therefore, numerous compounds, especially NRTIs have 
not been incorporated into this subset of LA therapeutics. Applying the conceptual 
framework of LASER ART, in which hydrophobic prodrugs are synthesized and 
subsequently nanoformulated, NRTIs were successfully included in the LA injectable 
paradigm. Proof of concept studies involving myristoylated 3TC and ABC laid the 
groundwork for what could be done with NRTIs in this arena.74,75 Building off this work 
and the concept of ProTide technology, a series of abacavir (ABC) prodrugs specifically 
designed to mask parent drug monophosphates with cleavable hydrophobic groups were 
synthesized.76 Furthermore, nanoformulations of these novel ABC prodrugs produced 
long-acting cellular depots of active carbovir-tripohsphate (CBV-TP).  
 Together these results suggest altering the physicochemical properties of ARVs 
by generating hydrophobic prodrugs can confer benefit in terms of PK and BD, as well 
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1.9 Figures 	  
 
Figure 1.9.1 HIV-1 Life cycle and ART targets.12	  	  
HIV-1 must attach to the CD4 receptor and subsequently a coreceptor (CCR5 or 
CXCR4) to gain cellular entry. Entry inhibitors such as MVC bind to CCR5 and prevent 
HIV-1 cellular entry. Furthermore, membrane fusion facilitated by HIV-1gp41 merges the 
viral and host cell membranes exposing viral RNA into the cytoplasm. Membrane fusion 
is disrupted by the fusion inhibitor Enfuvirtide. Reverse transcriptase converts single 
stranded RNA into double stranded DNA. This stage of the viral life cycle is inhibited by 
NRTIs, such as FTC, and NNRTIs, such as RPV. Viral DNA integration into the host cell 
genome is inhibited by integrase inhibitors (INI, DTG). Moreover, protease inhibitors 
prevent new virions from becoming mature and infectious by inhibiting the actions of 
protease (PI; Darunavir; DRV). Figure adapted from Maartens et al., HIV infection: 
epidemiology, pathogenesis, treatment, and prevention. Lancet, 2014. 
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Figure 1.9.2 LA HIV-1 maintenance therapy (LATTE-2).28	  	  
Following an oral induction period to achieve viral suppression, patients were 
administered CAB LA + RPV LA every 4 or 8 weeks or continued oral therapy 
(CAB,ABC,3TC). LA therapy demonstrated non-inferiority compared to oral therapy in 
this study. Figure adapted from Margolis et al., Long-acting intramuscular cabotegravir 
and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomized, 
open-label, phase 2b, non-inferiority trial. Lancet, 2017 
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Figure 1.9.3 LASER ART66	  	  
The apparent half-life of ART compounds can be potentially increased by prodrug 
modification and subsequent nanocrystal manufacture. Together, increased cellular 
uptake, storage, and slow intracellular release confer advantages over conventional LA 
ART. Figure adapted from Gendelman et al., The Promise of Long-Acting Antiretroviral 
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CHAPTER 2 
SYNTHESIS AND CHARACTERIZATION OF AN RPV 
PRODRUG LIBRARY 
 
2.1 Abstract 	  
RPV, a NNRTI, has been developed as a LAP (RPV LA). Combinations of RPV 
LA and CAB LA administered to HIV-1 infected individuals restrict HIV-1 replication and 
restores immune function. LA injectable formulations simplify treatment and prevention 
regimens. Notwithstanding, targeting HIV-1 cellular and anatomical reservoirs, and 
limiting injection volumes and dosage frequency remain ongoing obstacles for treatment 
optimization. In attempts to improve upon existing drug formulations, our laboratories 
developed LASER-ART, defined as synthesized prodrugs encased in nanocrystals with 
the intent to further extend drug half-life and improve viral reservoir delivery. To this end, 
an RPV prodrug library was synthesized and tested for its antiviral activity, 
nanoformulation capacity, as well as pharmacokinetics (PK) and biodistribution (BD) to 
ultimately generate a lead prodrug candidate for more extensive studies. 
2.2 Introduction 	  
ART has revolutionized the treatment of HIV-1 infected people from what was 
certain death to a life free of most co-morbid conditions.  Nonetheless, strict adherence 
to daily drug regimens is required to suppress viral replication and maintain CD4+ T cell 
numbers and functional immunity.  Nevertheless, a life span approaching that of the 
general population has been achieved2,3. The requirement for lifelong daily drug 
administration may soon be supplanted by LA dosage forms of ARVs such as implants 
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and injectable formulations77,78. LA formulations of common drugs have previously found 
utility as contraceptives and antipsychotics and parallel directives are now being 
considered for HIV-1 prevention and maintenance.79-81 As of now, HIV-1 LA agents have 
focused on parenteral cabotegravir (CAB-LA) and rilpivirine (RPV-LA) 52,82,83. Early 
success in the First LA Injectable Regimen (FLAIR) phase 3 trial examining monthly 
intramuscular (IM) injections found combination LA ART non-inferior to standard oral 
DTG, ABC, and 3TC.56 These results support prior LATTE and ATLAS trials with positive 
patient feedback and support for future LA ARVs.28,56,57 Therefore, anticipating a 
paradigm shift towards LA medicines, innovative approaches to advance formulation 
design are essential to limit current dosage volumes, injection site reactions, together 
with optimal tissue penetrance and dosing frequency.66 Alternative implantable devices 
also exhibit consistent and sustained drug release.60,61,64,84 However, the latter 
approaches require more sophisticated insertion and removal procedures and do not 
affect ARV delivery to viral reservoirs. As an alternative our own laboratories LASER-
ART utilizes ARV prodrug modifications to provide slow dissolution, penetrance of 
biological membranes, as well as sustained delivery of efficacious drug concentrations to 
both plasma and tissue reservoirs.67 LASER ART has been developed across a broad 
spectrum of ARVs and represents an innovative approach to improving existing LA 
formulations.70,71,76 Therefore, we aimed to synthesize a library of prodrugs for the non-
nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV), with the objective of 
developing a LA formulation designed to improve tissue distribution and prolong 
exposure of clinically relevant RPV concentrations. To this end, we synthesized a group 
of N-acyloxyalkyl RPV prodrugs of varying carbon chain length. Furthermore, prodrugs 
were evaluated based on their antiviral activity, nanoformulation capacity, and 
pharmacokinetic and tissue distribution profile in BALB/cJ mice to select a lead 
compound (M3RPV) for more extensive studies. 
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2.3 Materials and Methods 
2.3.1 Materials 	  
RPV was purchased from LeapChem (Hangzhou, China). Dichloromethane 
(DCM), tetrahydrofuran (THF), N,N-dimethylformamide (DMF), sodium(trimethylsilyl) 
amide (NaHMDS;1 M in THF), hexanes, ethyl acetate, dimethyl sulfoxide (DMSO), 
anhydrous pyridine, chloromethyl chlorosulfate, tetrabutylammonium hydrogen sulfate, 
potassium carbonate, heptanoic acid, lauroyl chloride, myristoyl chloride, stearic acid, 
zinc chloride (ZnCl2), sodium iodide (NaI), deuterated chloroform, paraformaldehyde 
(PFA), and Pluronic F127 (P407) was purchased from Sigma-Aldrich (St. Louis, MO). 
Pluronic F108 (P338) was purchased from BASF (Florham Park, NJ). Acetonitrile (ACN), 
methanol (MeOH), cell-culture grade water (endotoxin-free), and KH2PO4 were purchased 
from Fisher Scientific (Hampton, NH). Flash column chromatography was performed on 
32-63 µm flash silica gels, while thin layer chromatography utilized pre-coated silica 
plates (250 µm, F-254) both from SiliCycle Inc. (Quebec, Canada).  
2.3.2 Synthesis of chloromethyl heptanoate; chloromethyl stearate 	  
Heptanoic acid (or stearic acid) (1.0 eq.) was added to a mixture of K2CO3 (4.0 
eq.), tetrabutylammonium hydrogen sulfate (0.1 eq.), and H2O:DCM (1:1) at 0°C under 
argon atmosphere. Reaction mixture was warmed to RT for 10 min. Next, additional ice 
was added to cool the reaction and a solution of chloromethyl chlorosulfate (dissolved in 
DCM) was added dropwise and allowed to react overnight. After 16+ hours, the reaction 
was diluted with water and extracted with DCM (3x). Combined organic extracts were 
washed with brine and subsequently dried with sodium sulfate. Extracted samples were 
concentrated using a rotary evaporator to yield an oil. Silica column chromatography 
purification using 9:1 hexanes: ethyl acetate yielded a distinct band not visible by UV. 
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The purified compound was visualized by thin layer chromatography (TLC) staining with 
potassium permanganate. Furthermore, isolated samples was collected, concentrated 
and analyzed by 1H NMR. 
2.3.3 Synthesis of chloromethyl tetradecanoate; chloromethyl dodecanoate 	  
Myristoyl chloride (or Lauroyl chloride) was reacted with 1.0 eq. 
paraformaldehyde (PFA) and 0.025 eq. zinc chloride (ZnCl2) under reflux conditions for a 
minimum of 16 hours. The reaction mixture was cooled to RT and partitioned between 
dichloromethane (DCM) and saturated aqueous sodium bicarbonate in a separatory 
funnel. The aqueous layer was back-extracted twice with DCM. Organic extracts were 
combined, washed with brine and dried from sodium sulfate. The solvents were 
evaporated on a rotary evaporator followed by isolation of the desired compound using 
silica column chromatography eluting with a mobile phase of 9:1 hexanes-ethyl acetate 
and stained with potassium permanganate. 1H NMR characterized the isolated product 
to confirm appropriate chemical structure. 
2.3.4 Synthesis of iodomethyl heptanoate; dodecanoate; tetradecanoate; stearate 	  
Chloromethyl tetradecanoate (heptanoate; dodecanoate; stearate; 1 eq.) and 
sodium iodide (NaI, 2.5 eq.) were dissolved in a 2:1 mixture of ACN/DCM under an 
argon atmosphere. The reaction mixture proceeded for a minimum of 90 hours at RT 
under protection from light. Upon completion, the mixture was concentrated and 
partitioned between DCM and water. The aqueous layer was further extracted with DCM 
followed by sequential washing of the combined organic extracts with saturated sodium 
bicarbonate and brine. The sample solution was then dried from sodium sulfate, 
concentrated and purified by silica column chromatography eluting with 9:1 hexanes-
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ethyl acetate. Isolated compounds were analyzed by 1H NMR to confirm their chemical 
structure. 
2.3.5 M1RPV, M2RPV, M3RPV, M4RPV synthesis and characterization 	  
Rilpivirine hydrochloride (RPV HCl) was suspended in a mixture (1:1) of 
anhydrous tetrahydrofuran (THF) and dimethylformamide (DMF) under an argon 
atmosphere. The reaction flask was then cooled to -46°C (ACN; dry ice) followed by 
addition of 3 eq. of sodium bis(trimethylsilyl)amide (NaHMDS; 1M in THF) base and 
allowed to react for 30 min. to deprotonate the secondary amine in RPV. A solution of 
iodomethyl tetradecanoate (or heptanoate; dodecanoate; stearate) (1.5 eq.) in 
anhydrous THF was added dropwise, followed by gradual warming of the reaction 
mixture to room temperature and allowed to proceed for 48 hours. The mixture was then 
cooled to -78°C (Acetone; Dry Ice), quenched using MeOH and concentrated to remove 
solvents. The concentrated sample was purified by silica column chromatography eluting 
with 1:1 hexanes-ethyl acetate to isolate M1RPV, M2RPV, M3RPV, or M4RPV.  M3RPV 
was precipitated by hexanes for final product. Nuclear magnetic resonance (NMR) and 
Fourier-transform infrared (FTIR) spectroscopy, as well as positive electrospray 
ionization mass spectrometry (ESI-MS) were used to characterize each prodrug. Proton 
(1H)- and carbon (13C)- NMR spectra were recorded on a Varian Unity/Inova-500 NB 
(500 MHz; Varian Medical Systems Inc., Palo Alto, CA). FTIR was performed on a 
PerkinElmer universal attenuated total reflectance (UATR) Spectrum Two (Waltham, 
MA). M1RPV: 1H NMR (500 MHz, CDCl3): 7.98 (d, J = 5.8 Hz, 1H), 7.80 (d, J = 8.5 Hz, 
2H), 7.60 (d, J = 8.6 Hz, 2H), 7.23-7.34 (m, 4H), 5.88 (app. s, 2H), 5.51 (d, J = 5.8 Hz, 
1H), 2.33 (t, J = 7.4 Hz, 2H), 2.21 (s, 6H), 1.59 (p, J = 7.3 Hz, 6H), 1.18-1.34 (m, 6H), 
0.84 (t, J = 6.5 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 173.5, 161.5, 158.9, 157.4, 
149.4, 143.9, 141.2, 138.2, 133.8, 133.2, 128.2, 119.4, 118.4, 117.8, 104.4, 97.6, 
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97.2, 73.0, 34.7, 34.3, 31.3, 28.7, 25.0, 24.7, 22.4, 18.1, 13.9. MS-ES+ (m/z): calcd. 
for C30H32N6O2, 508.26 (100%), 509.26 (32.4%), 510.27 (2.7%); found, 509.2 [M+H+]. 
M2RPV: 1H NMR (500 MHz, CDCl3): 7.97 (d, J = 5.8 Hz, 1H), 7.81 (d, J = 8.6 Hz, 2H), 
7.60 (d, J = 8.6 Hz, 2H), 7.24-7.32 (m, 4H), 5.58-6.0 (m, 2H), 5.50 (d, J = 5.8 Hz, 1H), 
2.32 (t, J = 7.6 Hz, 2H), 2.21 (s, 6H), 1.59 (p, J = 7.3 Hz, 6H), 1.18-1.35 (m, 16H), 0.87 
(t, J = 6.9 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 173.5, 161.6, 158.9, 157.0, 149.4, 
143.9, 141.2, 138.2, 133.9, 133.2, 128.2, 119.5, 118.5, 117.8, 104.4, 97.7, 97.1, 73.1, 
34.3, 31.9, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 25.1, 24.8, 22.7, 18.2, 14.1. MS-ES+ 
(m/z): calcd. for C35H42N6O2, 578.34 (100%), 579.34 (37.9%), 580.34 (7.0%); found, 
579.4 [M+H+]. M3RPV: 1H NMR (500 MHz, CDCl3): 7.98 (d, J = 5.4 Hz, 1H), 7.79 (d, J = 
8.6 Hz, 2H), 7.60 (d, J = 8.3 Hz, 2H), 7.23-7.32 (m, 4H), 5.86-5.95 (m, 2H), 5.51 (d, J = 
5.8 Hz, 1H), 2.33 (t, J = 7.2 Hz, 2H), 2.21 (s, 6H), 1.51-1.68 (m, 6H), 1.17-1.32 (m, 17H), 
0.87 (t, J = 6.9 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 173.5, 161.5, 158.9, 157.7, 
149.4, 143.9, 141.2, 138.2, 133.8, 133.2, 128.2, 119.4, 118.3, 117.8, 104.4, 97.6, 
97.3, 73.0, 34.3, 31.9, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 24.8, 22.6, 18.2, 14.1. MS-
ES+ (m/z): calcd. for C37H46N6O2, 606.37 (100%), 607.37 (40.0%), 608.37 (7.8%); 
found, 607.2 [M+H+]. M4RPV: 1H NMR (500 MHz, CDCl3): 7.97 (d, J = 5.8 Hz, 1H), 7.81 
(d, J = 8.5 Hz, 2H), 7.59 (d, J = 8.5 Hz, 2H), 7.23-7.32 (m, 4H), 5.57-6.0 (m, 2H), 5.50 (d, 
J = 5.8 Hz, 1H), 2.33 (t, J = 7.5 Hz, 2H), 2.21 (s, 6H), 1.60 (p, J = 7.1 Hz, 2H), 1.18-1.32 
(m, 27H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 173.5, 161.5, 158.9, 
157.6, 149.4, 143.8, 141.2, 138.2, 133.8, 133.2, 128.2, 119.4, 118.3, 117.8, 104.4, 
97.6, 97.3, 73.0, 34.3, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 24.8, 22.7, 18.2, 
14.1. MS-ES+ (m/z): calcd. for C41H54N6O2, 662.43 (100%), 663.43 (44.3%), 664.44 
(9.6%); found, 663.2 [M+H+]. 
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2.3.6 Analysis of RPV prodrugs (M1-M4RPV) by UPLC-UV/Vis 	  
Analytical methods for drug quantitation were developed on UPLC-UV/Vis for 
RPV and each synthesized prodrug. Specifically, a Waters ACQUITY ultra performance 
liquid chromatography (UPLC) H-Class system with TUV detector and Empower 3 
software (Milford, MA) was used for quantification. RPV and all prodrugs (M1-M4RPV) 
were separated on a Phenomenex Kinetex 5 µm C18 column (150 x 4.6 mm) (Torrance, 
CA) with a flow rate of 1.0 mL/min. All compounds were quantified comparing peak 
areas to known standards (0.048-50 µg/mL) generating a linear standard curve.  
2.3.7 Macrophage half-maximum effective concentration (EC50) assays 	  
Studies to determine the EC50 of RPV and RPV prodrugs (M1RPV, M2RPV, 
M3RPV, and M4RPV) in MDMs were performed in 96-well plates at a density of 0.15 
x 106 cells/well. Specifically, cells were treated with 0.1-1000 nM (RPV or M1-M4RPV) 
for 2 hours, followed by HIV-1ADA challenge at a multiplicity of infection (MOI) of 0.1 
for 4 hours. Following viral challenge, cells were washed with PBS, and given fresh 
drug (0.1-1000 nM) containing media. Subsequently, cell supernatants were collected 
10 days later and assayed for RT activity.85,86 
2.3.7 Manufacture of nanoformulated RPV and RPV prodrugs  	  
Nanoformulations of RPV and RPV prodrugs (M1-M4RPV) were manufactured 
using an Avestin EmulsiFlex-C3 high-pressure homogenizer (Ottawa, ON, Canada). 
NRPV was prepared to best replicate Janssen’s RPV-LA currently in clinical trials.37 
Therefore, NRPV was prepared by dispersing P338 (0.5% w/v) in water and 
subsequently mixing RPV-free base (1% w/v) overnight at RT. Next, the pre-
suspension was homogenized (20,000 psi) to generate homogeneous nanocrystals. 
Nanoformulation physicochemical properties were evaluated by dynamic light 
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   22	  
scattering (DLS, Malvern Nano-ZS Worcestershire, UK) for size (nm), polydispersity 
index (PDI), and zeta potential (mV). Following homogenization, formulations were 
centrifuged (5,000 g for 5 min.) at which point the pellet was saved and the 
supernatant underwent a second round of centrifugation (10,000 g for 10 min). 
Resultant pellets were resuspended with desired volume of water and vortexed for 5 
min or until a uniform suspension was observed. Next, to remove aggregated 
particles, formulations were centrifuged (200 g for 3 min) and supernatants were 
collected and analyzed. Nanoformulation of RPV prodrugs (M1-M4RPV) followed a 
similar protocol with subtle differences. Specifically, P407 (0.5 % w/v) was used a 
surface stabilizer for NM1RPV, NM2RPV, and NM3RPV. Additionally, NM4RPV 
required the use of P338 (0.5% w/v) and Tween 80 (0.5% v/v) during its manufacture. 
All RPV prodrugs utilized 1% (w/v) drug concentrations for initial pre-suspensions.  
2.3.8 Murine PK and BD studies	  
Male BALB/cJ mice (6-8 weeks, Jackson Labs, Bar Harbor, ME) were treated 
with 45 mg/kg RPV eq. of NRPV, NM1RPV, NM2RPV, NM3RPV, or NM4RPV by 
intramuscular (IM; caudal thigh muscle) injection. Blood samples were collected into 
heparinized tubes by cheek puncture 24 hours after injection, followed by subsequent 
weekly collections. Isolated blood (25 µL) was immediately diluted in 1 mL of ACN 
and stored at -80°C until drug analysis. Remaining blood was centrifuged (2,000 g for 
5 min) and plasma supernatants were collected and stored at -80°C. For tissue 
collection, animals were humanly euthanized with isoflurane, followed by cervical 
dislocation 4 and 8 weeks after drug treatment. Spleen, lymph nodes, liver, lungs, 
kidneys, gut, and brain were collected to assay drug content.  
2.3.9 RPV plasma and tissue drug analysis by UPLC-MS/MS 	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Drug concentrations in plasma and tissue were determined by UPLC-MS/MS 
using a Waters ACQUITY UPLC-Xevo TQ-S micro mass spectrometry system 
(Milford, MA).  RPV was separated using an AQUITY UPLC-BEH shield RP18 column 
(1.7 um, 2.1 mm x 100 mm) using a 7 min gradient mobile phase consisting of A (7.5 
mM ammonium bicarbonate in Optima-grade water adjusted to pH 7 using acetic acid) 
and B (100% Optima-grade MeOH) at a flow rate of 0.25 mL/min. 70% mobile phase 
B remained for 4.75 min, followed by an increase to 95% B in 0.25 min and held 
constant for 0.75 min. Furthermore, mobile phase B was reset to 70% in 0.25 min and 
the column equilibrated for 1.0 min before the next injection. A cone voltage of 92 
volts and collision energy of 56 volts was used to detect RPV. Multiple reaction 
monitoring (MRM) transitions used for RPV, Indinavir (IDV) and Lopinavir (LPV) were 
367.032 > 127.859, 614.14 > 97.023, and 629.177 > 155.031 m/z respectively. 
Collected plasma was stored at -80°C until processing and analysis. Samples 
were processed by adding 1 mL of ice-cold ACN to 25 µL of plasma in a 1.7 mL 
eppendorf tube. Subsequently, 10 µL of IS (IDV 250 ng/mL; LPV 500 ng/mL; final 
concentrations of 25 ng/mL IDV + 50 ng/mL LPV) and 10 µL of 50% MeOH was added 
to each tube and were vortexed for 3 min. Next, samples were centrifuged (17,000 g for 
10 min) at 4°C and 1 mL of the supernatant was pipetted into a 2 mL tube. Furthermore, 
samples were dried under vacuum using a Thermo Scientific Savant SPD 1010 
Speedvac Concentrator (Waltham, MA) with no temperature. Resultant samples were 
reconstituted in 100 µL of 50% MeOH and vortexed for 3 min, followed centrifugation 
(17,000 g for 10 min). Subsequently, 50-60 µL of supernatant were loaded onto a 96-
well plate and used for UPLC-MS/MS analysis. Calibrations standards were prepared in 
a congruent fashion in which blank plasma was processed with IS and spiking solutions 
(2, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 8000, 10000 ng/mL) containing RPV 
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to generate standards with final analyte concentrations of 0.2, 0.5, 1, 2, 5, 10, 20, 50, 
100, 200, 500, 800, 1000 ng/mL respectively.  
Collected tissue was weighed (20-200 mg) and homogenized in 90% MeOH (5-
20x) using a Qiagen TissueLyser II (Hilden, Germany). Next, 100 µL of homogenate is 
spiked with 280 µL of MeOH and 10 µL IS (mixture of 200 ng/ml MDTG, 200 ng/mL 
SDRV, IDV 250 ng/mL, LPV 500 ng/mL, DTG-d3 2000 ng/mL, 80 ng/mL Lamivudine-
15N2-13C, 40 ng/mL Abacavir-d4). Samples were vortexed for 30 seconds, settled for 5 
min, and centrifuged (16,000 g for 15 min). For RPV analysis, 60 µL of supernatant was 
mixed with 40 µL of H2O and plated UPLC-MS/MS analysis. Calibration standards 
utilized a similar protocol using blank tissue homogenates and spiking solutions 
containing RPV at final analyte concentrations of 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100, 
200, 500 ng/mL.  
2.3.10 Statistics 	  
In-vivo study results were expressed as mean ± SEM with a minimum of 4 biological 
replicates. GraphPad Prism 7.0 software (La Jolla, CA) was used for all statistical 
analysis. Specifically, comparisons between two groups utilized student’s t test (two-
tailed). Significant differences were denoted as follows: (* P < 0.05, ** P < 0.01, *** P 
< 0.001, **** P < 0.0001). 
2.4 Results 
2.4.1 M1RPV synthesis and characterization 	  
M1RPV was synthesized by attaching a heptanoic acid moiety to RPV using a 
methylene ester linkage (Figure 2.6.1). 1H NMR confirmed the successful synthesis of 
M1RPV (Figure 2.6.2). Specifically, signals between 1.18-1.34 ppm represent the 
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repeating (R-CH2-R) protons, while protons of the methylene ester can be identified at 
5.88 ppm. Furthermore, Cα and terminal methyl protons are observed at 2.33 and 
0.84 ppm respectively. 13C NMR confirmed the presence of carbon atoms of the 
attached heptanoic acid linkage with the appearance of multiples signals between 
22.4 and 34.3 ppm.  FTIR was used to further characterize the structure of M1RPV 
(Figure 2.6.2). Specifically, M1RPV generated absorption bands at 1730, as well and 
(2864,2928,2954 cm-1), representing the carbonyl and alkane stretches of the 
heptanoic group respectively. To characterize and quantify M1RPV, an UPLC-UV/Vis 
method was developed (Figure 2.6.3). Specifically, using a mobile phase of 70% ACN 
and 30% H2O, a flow rate of 1.0 mL/min, and a detection wavelength of 230 nm, 
M1RPV was eluted at 7.72 minutes. A linear standard curve covering concentrations 
between 0.048-50 µg/mL was used for quantitation and analysis of future studies.  
2.4.2 M2RPV synthesis and characterization 	  
To generate M2RPV, RPV was modified with a 12-carbon fatty acid (Lauric acid) 
via a methylene ester linkage (Figure 2.6.1). To confirm successful synthesis, 1H NMR 
was performed (Figure 2.6.4). Specifically, signals at 0.84 and 2.32 ppm correspond to 
terminal methyl group and Cα protons respectively. Furthermore, multiplet signals 
between 1.18-1.35, as well as 5.58-6.0 represent (R-CH2-R) and methylene ester 
protons respectively. In addition, 13C NMR confirmed the presence of the aliphatic 
carbon atoms of the modifying lauric acid chain with signal between 22.7 and 34.3 ppm. 
Finally, FTIR further characterized the structure of M2RPV by revealing absorption 
bands at 1734 and (2854,2924 cm-1) representing the lauric carbonyl and alkane 
stretches respectively (Figure 2.6.4). An UPLC-UV/Vis method for M2RPV was 
developed using 90% ACN and 10% H2O as a mobile phase (Figure 2.6.5). Utilizing a 
flow rate of 1.0 mL/min and a detection wavelength of 230 nm, M2RPV was eluted at 
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5.61 minutes. Furthermore, a linear standard curve in the concentration range of 0.048-
50 µg/mL was used for quantitation and analysis.  
2.4.3 M3RPV synthesis and characterization 	  
M3RPV, which contains a bioreversible myristic acid moiety, was synthesized 
with a chemical yield of 53% (Figure 2.6.1). The proton NMR spectrum of M3RPV 
exhibited multiplet signals in the range of 5.86-5.95 and 1.17-1.32 ppm corresponding to 
the methylene ester and repeating (R-CH2-R) protons of the modifying lipid chain (Figure 
2.6.6). Additionally, chemical shifts at 0.87 and 2.33 ppm identified the terminal methyl 
group (CH3-R) and Cα protons of the fatty acid chain. The appearance of multiple signals 
between 22.6 and 34.3 ppm in the 13C NMR spectrum of M3RPV confirmed the 
presence of carbon atoms of the conjugated aliphatic chain. FTIR analysis produced 
absorption bands at 1726 cm-1 corresponding to the carbonyl (C=O) within the myristoyl 
group (Figure 2.6.6). Absorption bands at 2856 and 2924 cm-1 represented alkane 
stretches along the aliphatic carbon chain. Nitrile stretches characteristic of the RPV 
backbone were observed at 2218 cm-1. Detection by UPLC-UV/Vis was accomplished 
using a mobile phase of 90% ACN and 10% H2O, wavelength of 230 nm, and a flow rate 
of 1.0 mL/min to elute M3RPV at 8.58 minutes (Figure 2.6.7). A linear standard curve 
between 0.048-50 µg/ml was used for quantitation and analysis.  
2.4.4 M4RPV synthesis and characterization 	  
RPV was modified with an activated methylene ester of stearic acid to generate 
M4RPV (Figure 2.6.1). To confirm successful synthesis, 1H NMR was utilized (Figure 
2.6.8). In particular, multiplet signals between 5.57-6.0 and 1.18-1.32 ppm represent the 
methylene ester and (R-CH2-R) protons respectively. Furthermore, signals at 2.33 and 
0.88 ppm represent the Cα and terminal methyl group protons respectively. FTIR further 
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confirmed the structure of M4RPV (Figure 2.6.8). In addition to the characteristic nitrile 
absorption peak (2218 cm-1), M4RPV generated bands at 1730, as well as (2864, 2928, 
295 cm-1) representing the carbonyl and alkane stretches of stearate respectively. 
UPLC-UV/Vis analysis of M4RPV required a mobile phase consisting of 95% ACN and 
5% H2O and a flow rate of 1.0 mL/min (Figure 2.6.9). In addition, M4RPV was eluted at 
11.31 minutes using a detection wavelength of 230 nm. A linear standard curve between 
0.048-50 µg/mL as used for quantitation and analysis.  
2.4.5 Determination of half-maximum effective concentration of RPV prodrug  	  
Antiretroviral activity of RPV and RPV prodrugs (M1RPV; M2RPV; M3RPV; 
M4RPV) were determined in human monocyte-derived macrophages (MDMs) Figure 
2.6.10. RPV exhibited an EC50 value of 1.91 nM congruent with its published low to sub-
nanomolar in-vitro antiviral activities.30,31 Furthermore, EC50 values of RPV prodrugs 
decreased in conjunction with increased length of its carbon chain modification. 
Specifically, antiviral activities of 2.8, 3.1, 8.2, and 8.7 nM were observed for NM1RPV, 
NM2RPV, NM3PRV, and NM4RPV respectively.  
2.4.6 Manufacture and characterization of NRPV and (NM1-M4RPV) 	  
Nanoformulations were manufactured by a top-down approach utilizing high-
pressure homogenization. NRPV was manufactured to replicate RPV-LA developed by 
Janssen.37 Both NRPV and RPV-LA used P338 as a surface stabilizer, although the 
manufacturing technique differed, whereas NRPV used high-pressure homogenization, 
RPV-LA is manufactured by wet milling. Our laboratory generated NRPV exhibited an 
average size of 348 ± 51 nm compared with the reported 200 nm of RPV-LA. In terms of 
RPV prodrug formulations, NM1RPV (381 ± 119 nm, 0.3 ± .1, 32 ± 10 mV), NM2RPV 
(314 ± 59 nm, 0.3 ± .04, 15 ± 8 mV), NM3RPV (408 ± 41 nm, 0.2 ± .05, -17 ± 10 mV), 
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and NM4RPV (333 ± 32 nm, 0.3 ± .02, 19 ± 5 mV) all generated suitable 
nanoformulations for animal studies (Table 2.6.1).  
2.4.7 Murine PK and BD 	  
Nanoformulations of RPV and RPV prodrugs (NRPV; NM1RPV; NM2RPV; 
NM3RPV; NM4PRV) were administered to BALB/cJ mice to examine the effect of 
prodrug modification on plasma PK and tissue BD. Specifically, animals were 
administered a 45 mg/kg RPV eq. IM injection of NRPV or NM1RPV, NM2RPV, 
NM3RPV, or NM4RPV. Interestingly, 24 hours after injection, RPV concentrations in the 
plasma were dependent upon prodrug carbon chain length. (Figure 2.6.11) In particular, 
RPV plasma concentrations of 3370, 2714, 936.8, 111.2, and 133.52 ng/ml were 
observed for animals treated with NRPV, NM1RPV, NM2RPV, NM3RPV, and NM4RPV, 
respectively. Prodrug treatments of NM2RPV, NM3RPV, and NM4RPV all displayed 
shallower decay curves compared with NRPV and NM1RPV. Furthermore, 8 weeks after 
injection, RPV plasma concentrations in animals dosed with NM2RPV and NM4RPV 
were significantly higher than NRPV animals. Moreover, animals treated with select RPV 
prodrug formulations (NM2RPV, NM3RPV, NM4RPV) had significantly higher tissue 
concentrations compared with NRPV. Specifically, 8 weeks after injection, NM2RPV had 
significantly higher RPV concentrations in the liver and lymph nodes  compared with 
NRPV. Additionally, treatment with NM3RPV provided RPV concentrations of 9.6, 39.3, 
and 100.6 ng/g in the liver, spleen, and lymph node respectively 8 weeks after injection. 
(Figure 2.6.12-14) Moreover, NM4RPV treated animals generated significantly higher 
RPV concentrations in the liver and lymph nodes compared with NRPV 8 weeks after 
injection. 
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2.5 Discussion 	  
Our present study reports the synthesis of a diverse library of RPV prodrugs. 
Specifically, RPV was modified by aliphatic fatty acids of varying carbon chain lengths 
(7,12, 14, 18). Our investigation aimed to evaluate each prodrug on a number of metrics 
to ultimately determine a lead compound for more extensive study. To this end we 
evaluated the antiviral activity, nanoformulation capacity, and PK and BD characteristics 
of each prodrug. Synthesis of RPV prodrugs (M1-M4RPV) generated a library of 
compounds distinguished by their carbon chain length. We hypothesize that RPV was 
modified on its less hindered secondary amine. Our 1H NMR and mass spectrometry 
analysis confirmed the synthesis of prodrugs containing a single fatty acid modification. 
The presence of structural isomers within our sample, in which modification occurred at 
the more hindered secondary amine, remains a possibility. Analytical techniques 
combining ion-mobility-mass spectrometry (IM-MS) and molecular modeling have the 
potential to differentiate between structural isomers if they display differences in their 
gas phase conformations.87 Therefore, if it is deemed necessary, such a technology 
could be employed for a more precise chemical characterization. 
 Prodrug modification should be transient, ultimately releasing the active 
compound to exert its pharmacological purpose. To ensure modification of RPV with 
aliphatic carbon linkers did not completely abrogate antiviral activity we tested its ability 
to inhibit HIV-1ADA in MDMs. Interestingly, we observed a decrease in antiviral activity in 
the prodrugs modified with longer chain fatty acids. We hypothesize these observations 
are the result of slower bioconversion into RPV as the length of the fatty acid 
modification increases.88 Therefore observed changes in EC50 values could represent 
the presence of a mixture of intracellular species between the prodrug and active (RPV) 
form. Furthermore, with all prodrugs generating EC50 values < 10 nM all compounds 
proceeded for further analysis. 
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 PK and BD assessments in BALB/cJ mice revealed differences between NRPV 
and nanoformulated RPV prodrugs. Specifically, 24 hours after intramuscular injection, 
RPV plasma concentrations were higher for the shorter the fatty acid modifications (7, 
12). This suggests differences in RPV bioconversion between the prodrugs based upon 
the fatty acid chain length.88 Further studies testing the in vitro cleavage kinetics of each 
prodrug in mice plasma are required to confirm this hypothesis. Moreover, all prodrug 
formulations beside M1RPV produced shallower plasma decay kinetics compared with 
NRPV. Based on the observed differences in plasma kinetics, tissue samples (liver, 
lymph node, spleen) were processed to examine differences in distribution. Interestingly, 
significantly higher RPV concentrations were observed in the liver and lymph node for 
animals dosed with NM2RPV, NM3RPV, and NM4RPV when compared with NRPV. 
Furthermore, only NM3RPV generated significantly higher RPV concentrations in the 
spleen compared with NRPV.  
 Murine PK and BD provided evidence nanoformulated prodrugs of RPV may 
increase the apparent half-life and improved tissue distribution compared with NRPV. At 
the conclusion of our mouse study (8 weeks) NM2RPV and NM4RPV provided 
significantly higher RPV concentrations than NRPV, while NM3RPV trended towards 
significance. Furthermore, the lack of RPV present in the tissue of animals dosed with 
NRPV provided explanation for the continued decay of RPV plasma concentrations. In 
comparison, the significant RPV tissue distributions for NM2RPV, NM3RPV, and 
NM4RPV along with their shallow plasma decay curves generated our hypothesis that 
time points beyond 2 months could reveal significant differences in plasma and tissue 
RPV concentrations. Plasma concentrations of RPV were above the PA-IC90 (12.5 
ng/mL) for 35, 28, and 21 days following injection of NM2RPV, NM3RPV, and NM4RPV 
respectively. Our study used a dose of 45 mg/kg RPV eq. lower than clinical trials 
dosages (10 mg/kg) when converting for species differences between human and 
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mouse. Therefore future studies will deliver a more physiologically relevant dose of RPV 
to better evaluate the delivery of therapeutic plasma concentrations. Furthermore, follow-
up studies should quantify prodrug concentrations in tissue to better understand the 
present data.   
 Our current study provided proof-of-concept that nanoformulated prodrugs of 
RPV could modify the tissue distribution and plasma decay kinetics compared with 
NRPV. To further optimize our approach we aimed to select a lead prodrug candidate 
from our research. In our mice studies, M1RPV exhibited precipitous decline of plasma 
RPV and was not detected in tissue, thus not recommended for further work. 
Nanoformulation of M2RPV (NM2RPV) yielded low drug concentrations and was difficult 
to resuspend after centrifugation. This required an injection in each mouse leg, not a 
single injection as with the other nanoformulations. While, M2RPV may have future 
application when using direct-manufacture formulation design, we decided to not move it 
forward to the next phase of our studies. M3RPV and M4RPV generated similar plasma 
RPV drug levels, but ultimately, NM3RPV generated significantly higher RPV levels in 
the spleen. Therefore, our future studies will center upon M3RPV and its potential as a 
long-acting HIV-1 therapeutic.  
 





2.6 Figures  
 
 
Figure 2.6.1 Synthesis and bioconversion of RPV prodrugs 	  
Rilpivirine was modified with variable fatty acid chain lengths (7, 12, 14, 18) to develop a 
prodrug library (M1RPV, M2RPV, M3RPV, M4RPV). Prodrug bioconversion is 
hypothesized to first proceed by enzymatic cleavage of the methylene ester, yielding N-
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Figure 2.6.2 M1RPV chemical characterization 	  
(A) Proton NMR spectra confirmed the synthesis of a heptanoyloxymethyl prodrug of 
RPV (M1RPV). Specifically, signals between 1.18-1.34 ppm represent the repeating (R-
CH2-R) protons, while protons of the methylene ester can be identified at 5.88 ppm. 
Furthermore, Cα protons, as well as those from the terminal methyl group are observed 
at 2.33 and 0.84 ppm respectively. (B) 13C NMR spectra confirms the presence of 
aliphatic carbon chain with multiple signals between 22.4 and 34.3 ppm. (C) FTIR 
analysis of M1RPV generated absorption bands at 1730, as well as (2864, 2928, 2954), 
representing the heptanoic acid carbonyl and alkane stretches respectively. (D) Positive 
electrospray ionization mass spectrometry (ESI-MS) analysis generated a strong signal 
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Figure 2.6.3 Detection of M1RPV by UPLC-UV/Vis.  	  
M1RPV (50 µg/mL) detected by UPLC-UV/Vis using a mobile phase of 70% (ACN) and 
30% H2O, wavelength of 230 nm, and a flow rate of 1.0 mL/min to produce a peak at 
7.72 minutes. A linear standard curve between 0.048-50 µg/mL was used for 
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Figure 2.6.4 M2RPV chemical characterization 	  
(A) Proton NMR confirmed the synthesis of a lauroyloxymethyl prodrug of RPV 
(M2RPV). Specifically, multiplet signals between 1.18-1.35 and 5.58-6.0 represent (R-
CH2-R) and methylene ester protons respectively. Moreover, signals at 0.84 and 2.32 
correspond to terminal methyl group and Cα protons respectively. (B) 13C NMR spectra 
confirms the presence of aliphatic carbon chain with multiple signals between 22.7 and 
34.3 ppm. (C) FTIR analysis of M2RPV generated absorption bands at 1734, as well as 
(2854, 2924), representing the lauric acid carbonyl and alkane stretches respectively. 
(D) Positive electrospray ionization mass spectrometry (ESI-MS) analysis generated a 
strong signal for M2RPV at 579.4 m/z. 
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Figure 2.6.5 Detection of M2RPV by UPLC-UV/Vis.  	  
M2RPV (50 µg/mL) detected by UPLC-UV/Vis using a mobile phase of 90% (ACN) and 
10% H2O, wavelength of 230 nm, and a flow rate of 1.0 mL/min to produce a peak at 
5.61 minutes. A linear standard curve between 0.048-50 µg/mL was used for 
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Figure 2.6.6 M3RPV chemical characterization 	  
(A) Proton NMR spectra confirmed they synthesis of a myristoyloxymethyl prodrug of 
RPV (M3RPV). Specifically, multiplet signals between 5.86-5.95 and 1.17-.132 ppm, 
which correspond to the methylene ester and repeating (R-CH2-R) protons 
respectively. In addition, Cα and terminal methyl group protons are identified at 2.33 
and 0.87 ppm respectively. (B) 13C NMR spectra confirms the presence of aliphatic 
carbon chain with multiple signals between 22.6 and 34.3 ppm. (C) FTIR analysis of 
M3RPV generated absorption bands at 1726, as well as (2856, 2924), representing the 
myristoyl carbonyl and alkane stretches respectively. (D) Positive electrospray ionization 
mass spectrometry (ESI-MS) analysis generated a strong signal for M3RPV at 607.2 
m/z. 
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Figure 2.6.7 Detection of M3RPV by UPLC-UV/Vis.  	  
M3RPV (50 µg/mL) detected by UPLC-UV/Vis using a mobile phase of 90% (ACN) and 
10% H2O, wavelength of 230 nm, and a flow rate of 1.0 mL/min to produce a peak at 
8.58 minutes. A linear standard curve between 0.048-50 µg/mL was used for 
quantitation and analysis. 
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Figure 2.6.8 M4RPV chemical characterization 	  
(A) Proton NMR spectra confirmed the synthesis of a stearoyloxymethyl prodrug of RPV 
(M4RPV). Specifically, multiplet signals between 5.57-6.0 and 1.18-1.32 ppm represent 
the methylene ester and (R-CH2-R) protons respectively. In addition, signals at 2.33 and 
0.88 ppm represent the Cα and terminal methyl group protons respectively. (B) 13C NMR 
spectra confirms the presence of aliphatic carbon chain with multiple signals between 
22.7 and 34.3 ppm. (C) FTIR analysis of M4RPV generated absorption bands at 1732, 
as well as (2852, 2918), representing the stearic acid carbonyl and alkane stretches 
respectively. (D) Positive electrospray ionization mass spectrometry (ESI-MS) analysis 
generated a strong signal for M4RPV at 663.2 m/z. 
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Figure 2.6.9 Detection of M4RPV by UPLC-UV/Vis.  	  
M4RPV (50 µg/mL) detected by UPLC-UV/Vis using a mobile phase of 95% (ACN) and 
5% H2O, wavelength of 230 nm, and a flow rate of 1.0 mL/min to produce a peak at 
11.31 minutes. A linear standard curve between 0.048-50 µg/mL was used for 
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Figure 2.6.10 Antiviral activity of RPV prodrug in MDMs.  	  
The antiviral activities of RPV and synthesized prodrugs (M1-M4RPV) were tested at a 
range of concentrations (0.1-1000 nm) in MDMs. RT activity was determined after viral 
challenge with HIV-1ADA. Data was normalized and expressed as a percentage of HIV-1 
control (mean ± SEM) with a minimum of 3 biological replicates. 
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Figure 2.6.11 RPV prodrug PK  	  
Male BALB/cJ mice were treated with 45 mg/kg RPV-eq. by intramuscular injection (IM) 
of NRPV, NM1RPV, NM2RPV, NM3RPV, or NM4RPV. RPV plasma concentrations 
were analyzed weekly for a period of 2 months by UPLC-MS/MS. Data is expressed as 
mean ± SEM where n = 4/5 biological replicates. 
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Figure 2.6.12 RPV prodrug liver tissue distribution 	  
Male BALB/cJ mice were treated with 45 mg/kg RPV-eq. by intramuscular injection (IM) 
of NRPV, NM1RPV, NM2RPV, NM3RPV, or NM4RPV. Liver samples were collected 28 
and 56 days post injection to assess RPV tissue concentrations by UPLC-MS/MS. Data 
is expressed as mean ± SEM where n = 4/5 biological replicates (**** P < 0.0001, *** P < 
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Figure 2.6.13 RPV prodrug spleen tissue BD 	  
Male BALB/cJ mice were treated with 45 mg/kg RPV-eq. by intramuscular injection (IM) 
of NRPV, NM1RPV, NM2RPV, NM3RPV, or NM4RPV. Spleen samples were collected 
28 and 56 days post injection to assess RPV tissue concentrations by UPLC-MS/MS. 
Data is expressed as mean ± SEM where n = 4/5 biological replicates (** P < 0.01 by 
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Figure 2.6.14 RPV prodrug lymph node tissue BD 	  
Male BALB/cJ mice were treated with 45 mg/kg RPV-eq. by intramuscular injection (IM) 
of NRPV, NM1RPV, NM2RPV, NM3RPV, or NM4RPV. Lymph node samples were 
collected 28 and 56 days post injection to assess RPV tissue concentrations by UPLC-
MS/MS. Data is expressed as mean ± SEM where n = 4/5 biological replicates (*** P < 
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2.7. Table 
Table 2.7.1. Manufacture and characterization of nanoformulated RPV prodrugs 
RPV and synthesized prodrugs (M1RPV, M2RPV, M3RPV, M4RPV) were 
nanoformulated using high-pressure homogenization and centrifugation as a means of 
purification and concentration respectively. Formulations were characterized in terms of 
size (nm), polydispersity (PDI), and zeta potential (mV) by dynamic light scattering 









Formulation Manufacture/Process Excipients Purification
NRPV High)Pressure.Homogenization P338 Centrifugation
NM1RPV High)Pressure.Homogenization P407 Centrifugation
NM2RPV High)Pressure.Homogenization P407 Centrifugation
NM3RPV High)Pressure.Homogenization P407 Centrifugation
NM4RPV High)Pressure.Homogenization P338,.Tween.80 Centrifugation
Formulation Hydrodynamic/Diameter/(nm) Polydispersity/(PDI) Zeta/Potential/(mV)
NRPV 348.±.51.nm 0.23.±..03 10.±.6.mV
NM1RPV 381.±.119.nm 0.28.±..12 32.±.10.mV
NM2RPV 314.±.59.nm 0.27.±..04 15.±.8.mV
NM3RPV 408.±.41.nm 0.18.±..05 .)17.±.10.mV
NM4RPV 333.±.32.nm 0.32.±..02 19.±.5.mV
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CHAPTER 3 




3.1 Introduction 	  
Current ART has revolutionized patient care for those infected with HIV-1. 
Specifically, individuals faithfully adherent to oral ART experience undetectable plasma 
viral loads, improved immune function, as well as an extended life span.2,3 Transitioning 
towards the next generation of ART, scientists have been learning from the past, 
specifically studying LA formulations developed for contraception and schizophrenia.44,46 
It is well established patient adherence is severely lacking, even in the context of clinical 
trials.90 Lack of adherence in the context of HIV-1 can be particularly deleterious. 
Consistent, efficacious plasma concentrations of ARVs are necessary to achieve viral 
suppression. Moreover, suboptimal PK due to missed doses can cause low levels of 
viral replication and generate resistance mutations.91 To address these concerns, LA 
formulations of RPV and CAB (RPV-LA; CAB-LA) are under development.52,82 Phase 3 
clinical trials demonstrated that LA regimens administered monthly were non-inferior to 
standard oral ART, thus a LA revolution in ART therapy is on the horizon.28,56 LA ART is 
in its inception, thus its limitations require further optimization. Generally, increasing 
dosing intervals beyond a month towards a bi-annual goal would make the therapy more 
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attractive to patients for maintenance and PrEP alike. Therefore, our previous work has 
demonstrated that generating hydrophobic prodrugs of existing ARVs and manufacturing 
LASER-ART formulations could substantially improve PK and BD.66,67,70,71 Our current 
work reports the nanoformulation and testing of a myristoylated RPV prodrug 
(NM3RPV). NM3RPV generated RPV plasma concentrations above the PA-IC90 for 25 
weeks, while concurrently producing a substantial tissue depot, after in single IM 
injection in BALB/cJ mice. Furthermore, NM3RPV provided 13- and 26-fold increases in 
RPV t1/2 and MRT, respectively, compared with NRPV. Therefore, our current work 
demonstrates proof-of-concept for the development and further optimization of 
nanoformulated RPV prodrugs 
3.2 Materials and Methods 
3.3.1 Reagents 	  
RPV was purchased from LeapChem (Hangzhou, China). Ciprofloxacin, 
paraformaldehyde (PFA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), 3,3’-diaminobenzidine (DAB) and pluronic F127 (P407) was purchased from 
Sigma-Aldrich (St. Louis, MO). Pluronic F108 (P338) was purchased from BASF 
(Florham Park, NJ). Acetonitrile (ACN), methanol (MeOH), cell-culture grade water 
(endotoxin-free), KH2PO4, bovine serum albumin (BSA), Triton X-100, and gentamicin 
were purchased from Fisher Scientific (Hampton, NH). Dulbecco’s Modified Eagle 
Medium (DMEM) was purchased from Corning Life Sciences (Tewksbury, MA). Polymer-
based HRP-conjugated anti-mouse Envision+ secondary antibody was purchased from 
Dako (Carpinteria, CA). 
3.3.2 Quantification of RPV and M3RPV by UPLC-UV/Vis  	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Drug concentration was assayed on a Waters ACQUITY ultra performance 
liquid chromatography (UPLC) H-Class system with TUV detector and Empower 3 
software (Milford, MA). RPV and M3RPV samples were separated on a Phenomenex 
Kinetex 5 µm C18 column (150 x 4.6 mm) (Torrance, CA). RPV was detected at 285 
nm, using a mobile phase consisting of 65% (50 mM KH2PO4 pH 3.2) and 35% (ACN) 
and a flow rate of 1.0 mL/min. M3RPV was detected at 230 nm, using a mobile phase 
consisting of 90% ACN and 10% H2O and a flow rate of 1.0 mL/min. Drug content was 
determined relative to peak areas from drug standards (0.05-50 µg/mL). 
3.3.3 Solubility 	  
Aqueous and 1-octanol solubility were evaluated by mixing excess RPV in 
each solvent for 24 hours. Centrifugation at 20,000 g for 10 min pelleted any 
undissolved drug. Aqueous supernatants were frozen, lyophilized, and subsequently 
re-suspended in MeOH for analysis. 1-Octanol supernatants were prepared for 
analysis by dilution into MeOH. Collected samples were analyzed for drug content by 
UPLC-UV/Vis as described above. 
3.3.4 Nanoparticle manufacture and characterization 	  
Nanoformulations of RPV and M3RPV (NRPV and NM3RPV) were 
manufactured using an Avestin EmulsiFlex-C3 high-pressure homogenizer (Ottawa, 
ON, Canada). NRPV was prepared to best replicate Janssen’s RPV-LA currently in 
clinical trials.37 Specifically, P338 1% (w/v) was dispersed in H2O, followed by the 
addition of 10% (w/v) RPV-free base and mixing overnight. Similarly, NM3RPV 
contained 2.1% P407 and 21% M3RPV in H2O. Formulations were homogenized at 
(20,000 psi) to generate homogeneous nanocrystals of uniform size and 
polydispersity (pdi). Nanoparticle physicochemical characterization for size (nm), 
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polydispersity (PDI) and zeta potential (mV) were evaluated by dynamic light 
scattering (DLS, Malvern Nano-ZS Worcestershire, UK). NM3RPV and NRPV drug 
quantitation was analyzed by UPLC-UV/Vis as described above. 
3.3.5 Macrophage cellular uptake and retention studies 	  
Human monocytes were obtained by leukapheresis from HIV-1/2 seronegative 
donors and subsequently purified by counter-current centrifugal elutriation.92 
Monocytes were grown in culture media containing DMEM (4.5 g/L glucose, L-
glutamine, and sodium pyruvate) supplemented with 10% pooled human serum (heat-
inactivated), 10 µg/mL ciprofloxacin, and 50 µg/mL gentamicin. Additionally, cells 
were maintained at 37°C in a 5% CO2 incubator. Human monocytes were plated in 12, 
24, or 96-well plates at 1.0x106, 0.5x106, or 0.15x106 cells/mL respectively. 
Recombinant human macrophage colony stimulating factor (MCSF, 1000 U/mL) was 
added to culture media for 7 days to facilitate monocyte-derived macrophages 
(MDMs) differentiation and vitality in culture. MDM uptake and retention studies were 
performed in 12-well plates, with each treatment group completed in triplicate. Briefly, 
MDMs were treated with NM3RPV or NRPV at concentrations of 10 or 30 µM and 
cells were collected 1, 2, 4, 8 hours later. For cellular retention studies, drug was 
removed after 8 hours. Cells were washed with PBS and replenished with fresh 
media. Cellular samples were collected at 1, 5, 10, 20 and 30 days to assay 
intracellular drug concentration. For both studies, MDMs were collected by removing 
media, PBS washing, and scraping the cells into suspension. Cells were subsequently 
counted using an Invitrogen Countess Automated Cell Counter (Carlsbad, CA). 
Collected MDMs were centrifuged at 3,000 rpm for 8 min. Cell pellets were sonicated 
in MeOH to extract intracellular drug and subsequently centrifuged at 14,000 rpm for 
10 min. Samples were analyzed by UPLC-UV/Vis for intracellular drug content as 
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described above. Furthermore, to test cytotoxicity, an MTT was performed. Briefly, 
MDM were plated in 96-well plates at a density of 0.15 x 106 cells per well and treated 
with NRPV or NM3RPV (1-1000 µM) for a period of 8 hours. After treatment, cells 
were washed and incubated with MTT solution (5 mg/mL; 100 µL/well) at 37°C for 45 
min. Next, MTT was aspirated and 200 µL of DMSO was subsequently added. Plates 
were gentled shaken to mix and absorbance was measured on a Molecular Devices 
SpectraMax M3 plate reader with SoftMax Pro 6.2 software (Sunnyvale, CA) at 490 
nm.  
3.3.6 Assay of antiretroviral activities in MDM 	  
To assess long-term antiretroviral activity, MDMs were plated in 24-well plates 
at a density of 0.5 x 106 cells/well. Cells were treated with 10 or 30 µM NM3RPV or 
NRPV for 8 hours, followed by a PBS wash and addition of fresh media. Cells were 
then challenged with HIV-1ADA at a multiplicity of infection (MOI) 0.1 at 1, 5, 10, 20 or 
30 days after treatment for 16 hours. After viral challenge, cells were washed with 
PBS and replenished with fresh media. Supernatants were collected 10 days after 
challenge and assayed for reverse transcriptase (RT) activity.85,86 Replicate cells were 
fixed with 4% PFA and stained for HIV-1 p24 antigen by immunohistochemistry.86 
3.3.7 Plasma cleavage kinetics 	  
Plasma cleavage kinetics of M3RPV was evaluated from mouse, rat, rabbit, 
dog, monkey, and human plasma. M3RPV (1 µM) was incubated in 100 µL plasma at 
37°C. At 0, 2, 6, and 24 hours samples were quenched with 1 mL of MeOH and 
vortexed for 3 min. Samples were the centrifuged at 15,000 g for 10 min; upon which 
supernatants were analyzed for RPV and/or M3RPV by UPLC-MS/MS. Heat-
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inactivated plasma was used as a negative control for enzymatic cleavage and 
hydrolysis testing.  
3.3.8 Transmission Electron Microscopy (TEM) 	  
Morphology of NRPV and NM3RPV was assessed by FEI Tecnai G2 Spirit 
TEM (Hillsboro, OR) using negative staining. Briefly, 10 µL of diluted nanoformulation 
was applied to a formavar/silicone monoxide coated 200 mesh copper grid and 
allowed to absorb for 5 min. Excess samples were removed with filter paper and 
subsequently dried for an additional 2-5 minutes. Next, Nanovan negative stain was 
pipetted onto the grid for staining before imaging under TEM. 
3.3.9 Pharmacokinetics (PK) and biodistribution (BD) 	  
Male BALB c/J mice (6-8 weeks, Jackson Labs, Bar Harbor, ME) were 
administered 45, 75, or 100 mg/kg RPV-eq. NM3RPV or NRPV by a single 
intramuscular (IM; caudal thigh muscle) injection at 40 µL/ 25 g. Following injection, 
blood samples were collected into heparinized tubes 24 hours later, as well as weekly 
for the 46 week study duration. Collected blood (25 µL) was immediately diluted into 1 
mL ACN and stored at -80°C until drug analysis. Remaining blood samples were 
centrifuged at 2,000 g for 5 min. Plasma supernatants were collected and stored at -
80°C until further analysis. Animals were humanly euthanized with isoflurane, followed 
by cervical dislocation at 56 and 323 days after drug treatment to obtain spleen, 
lymph node, liver, lung, gut, kidney, brain and rectal tissue for drug content 
determinations. Drug concentrations in plasma, tissue and whole blood were 
determined by UPLC-MS/MS using a Waters ACQUITY UPLC-Xevo TQ-S micro mass 
spectrometry system (Milford, MA).  RPV was separated using an AQUITY UPLC-
BEH shield RP18 column (1.7 µm, 2.1 mm x 100 mm) using a 7 min gradient mobile 
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phase consisting of A (7.5 mM ammonium bicarbonate in Optima-grade water 
adjusted to pH 7 using acetic acid) and B (100% Optima-grade MeOH) at a flow rate 
of 0.25 mL/min. Initial conditions of 70% mobile phase B remained for 4.75 min, 
followed by an increase to 95% B in 0.25 min and held constant for 0.75 min. Mobile 
phase B was reset to 70% in 0.25 min and the column equilibrated for 1.0 min before 
the next injection. A cone voltage of 92 volts and collision energy of 56 volts was used 
to detect RPV. Multiple reaction monitoring (MRM) transitions used for RPV, indinavir 
and lopinavir were 367.032 > 127.859, 614.14 > 97.023, and 629.177 > 155.031 m/z 
respectively. M3RPV was separated using an ACQUITY UPLC BEH C18 1.7 µm 
analytical column (2.1 mm x 30 mm) with an ACQUITY BEH C18 Vanguard column 
using a flow rate of 0.28 mL/min. MRM transitions of 607.34 < 379.09 m/z were used 
for quantification, while 60.734 < 367.12 and 607.34 < 363.12 m/z were used for 
identity confirmation. Mobile phase A (7.5 mM ammonium formate in water, adjusted 
to pH 3.0 with formic acid) and mobile phase B (100% MeOH) ran isocratic at 15 % A 
for 5 minutes. In order to wash the column, mobile phase A decreased to 5% for 1 
min, then returning to 15% over the next 2 min. For drug analysis 50 µL of plasma 
was mixed with 1 mL of ice cold ACN and subsequently spiked with 10 µL of internal 
standards. (IS; MDTG and 15N2-13C-Lamivudine) Samples were subsequently vortexed 
(3 min) and centrifuged (17,000 g for 10 min). Supernatants were dried, reconstituted, 
and injected for UPLC-MS/MS analysis. Plasma standards were extracted at a final 
concentration of 0.1-1000 ng/ml. Tissue analysis required between 20-200 mg of 
tissue (spleen, lymph node, liver, gut, lung, kidney, brain, rectal) to be diluted with 
90% MeOH and homogenized. Tissue homogenates were mixed with MeOH 
containing IS and vortexed (3 min), followed by centrifugation (17,000 g for 10 min). 
Supernatants were collected and mixed with H2O for UPLC-MS/MS analysis. Tissue 
standards were extracted at a final concentration of 0.05-500 ng/g. 
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3.3.10 NM3RPV PK in rhesus macaques 	  
Male rhesus macaques (4.4-6.7 kg; PrimeGen) were anesthetized with 
ketamine (10 mg/kg) and subsequently administered 45 mg/kg RPV eq. of NM3RPV 
by IM injection (0.5 mL/kg) in the gluteus maximus. Blood samples were collected in 
potassium-EDTA coated tubes for blood cell counts, serum metabolites and plasma 
drug quantitation. At 204 days after treatment lymph node, adipose tissue and rectal 
tissue biopsies were performed in anesthetized animals for for drug quantitation. 
3.3.11 PK parameter analyses 	  
 Non-compartmental PK analyses for plasma RPV were performed using 
WinNonlin-5.1 (Certara USA, Inc., Princeton, NJ, USA) for BALB/cJ mice studies. 
3.3.12 NM3RPV Pharmacodynamics in a humanized mouse model of HIV-1 
infection 	  
NOD/scid-IL-2Rγcnull (NSG) mice were reconstituted with CD34+ human 
hematopoietic stem cells (HSC) isolated from umbilical cord blood.93 Mice were 
administered NM3RPV (100 mg/kg RPV eq.; IM) and subsequently challenged with 
HIV-1ADA (1 x 104 TCID50; Intraperitoneal; IP) two weeks following drug treatment. 
Two and 4 weeks after viral challenge blood was collected by cheek puncture into 
EDTA-coated tubes. Blood samples were centrifuged (2,000 g for 5 min) and collected 
plasma was stored at -80°C until further analyses. Viral load (HIV-1 RNA) was 
quantified in collected plasma samples using a Roche Amplicor and TaqMan-48 
system. Additionally, plasma drug concentrations were determined by UPLC-MS/MS. 
3.3.13 Statistics 	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In-vitro studies were expressed as mean ± SEM with a minimum of 3 biological 
replicates, while in-vivo study results were expressed as mean ± SEM with a minimum 
of 4 biological replicates. GraphPad Prism 7.0 software (La Jolla, CA) was used for all 
statistical analysis. Specifically, comparisons between two groups utilized student’s t 
test (two-tailed). Significant differences were denoted as follows: (* P < 0.05, ** P < 
0.01, *** P < 0.001, **** P < 0.0001). 
3.4 Results 
3.4.1 M3RPV Solubility, Cleavage Kinetics, and Antiviral Activity  	  
Prodrug synthesis enabled precise alteration of a RPV’s physicochemical 
properties. M3RPV exhibited a 2.4-fold decrease in water (**P < 0.01) and an 8.7-fold 
increase in 1-octanol solubility (****P < 0.0001) (Figure 3.6.1). This data underscores the 
changes in hydrophobicity and lipophilicity generated by prodrug modification. As most 
prodrugs are pharmacologically inactive and require enzymatic or hydrolytic activation, 
we tested cleavage kinetics of M3RPV in mouse, rat, rabbit, dog, monkey, and human 
plasma (Figure 3.6.2). Interestingly, species-specific kinetic differences were observed, 
whereby mouse plasma produced the most robust cleavage (94.8%) and human plasma 
exhibited slower prodrug breakdown (15.7%) over a 24-hour period. As successful 
bioconversion requires removal of the inactive moiety and release of the active 
compound we analyzed RPV formation during plasma cleavage. M3RPV incubated in 
mouse plasma efficiently released 70% of RPV within 24 hours. In comparison dog, 
human and monkey yielded 5, 14, and 21% RPV, respectively. Furthermore, to 
demonstrate there was not an abrogation of activity due to prodrug modification, M3RPV 
was tested against HIV-1 in both MDM and CD4+ T-cells (CEM) (Figure 3.6.3). 
Compared to RPV, M3RPV exhibited a 4.3-fold increase in EC50 for viral inhbition in 
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MDM (EC50 of 1.9 vs 8.2 nM), and a 6.8-fold increase (EC50 of 0.8 vs 5.5 nM) in CEM T-
cells.  
3.4.2 Nanoformulation characterization and particle stability 	  
NRPV and NM3RPV were manufactured by top down synthesis utilizing high-
pressure homogenization to generate stable nanosuspensions. Poloxomer (P338 and 
P407) surfactants provided particle surface stabilization for NRPV and NM3RPV. As 
clinically relevant injectable formulations must maintain their physical integrity within a 
range of storage conditions DLS was used to assess physicochemical stability of NRPV 
and NM3RPV at room temperature, 4, and 37°. Both formulations maintained particle 
size, polydispersity (pdi), and zeta potential for a period of 100 days. Specifically, the 
initial size (277 ± 9 nm), pdi (0.24 ± .02), and zeta potential (-9.2 ± 0.3 mV) of NRPV 
exhibited a subtle size reduction over the course of testing (239 ± 3 nm, 0.25 ± .01, -13.6 
±. 0.7 mV at day 100. (Figure 3.6.4) NM3RPV had an average particle size of 345 ± 5 
nm, pdi of 0.18 ± .06 and zeta potential of -17.6 ± 0.6 mV at the time of manufacture. 
One hundred days later, physicochemical parameters of NM3RPV were stable (326 ± 1 
nm, 0.25 ± 0.1 and -9.2 ± 0.9 mV. (Figure 3.6.4) Furthermore, temperature variation (4 
or 37°) did not change the physical integrity of either NRPV or NM3RPV (Figure 3.6.4) 
Transmission electron microscopy (TEM) of both NRPV and NM3RPV displayed 
nanocrystals of an elongated cuboidal morphology (Figure 3.6.5). Importantly, we next 
investigated prodrug stability within NM3RPV over time. NM3RPV contained 99.72% 
M3RPV when analyzed for both prodrug and parent (RPV) compounds by UPLC UV/Vis 
after initial manufacture. By day 100 the percentage remained consistent for NM3RPV at 
RT and 4° (99.69 and 99.71%), while a decreasing trend was observed in formulation 
stored at 37°C (99.42%) (Figure 3.6.6). Furthermore, pharmacokinetic (PK) tests of 
NM3RPV were performed in BALB/cJ mice comparing freshly made formulations to 
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those stored at RT for 90 days. RPV plasma levels were comparable between the two 
formulations during the 147-day study period (Figure 3.6.6). 
3.4.3 NM3RPV-macrophage interactions 	  
The phagocytic nature of macrophages affords testing of their use as cellular 
drug depots. We reasoned that packaging of drug nanocrystals at sites of viral growth 
would facilitate the drug’s antiretroviral activities. We therefore evaluated uptake of 
NM3RPV and NRPV in MDM at 10 and 30 µM doses. Drug formulations administered at 
10 µM resulted in comparable intracellular drug levels after 8 hours for NM3RPV (2.0 
µg/106 cells) and NRPV (2.2 µg/106 cells). (Figure 3.6.7) A 30 µM treatment led to drug 
concentrations of 6.0 µg/106 and 4.9 µg/106 cells for NRPV and NM3RPV, respectively. 
(Figure 3.6.9) Furthermore, NM3RPV treated cells generated detectable intracellular 
RPV concentrations of 95 and 140 ng/106 cells at 8 hours after 10 and 30 µM of drug 
exposure.  As macrophages also have the capacity to migrate throughout the body, 
thereby serving as drug delivery systems to viral reservoirs, we tested their capacity to 
retain intracellular drug over a 30-day period following a single drug loading. Single 
exposure of MDM to 10 or 30 µM of NM3RPV showed enhanced intracellular drug over 
NRPV. Specifically, the amount of prodrug retained by MDM was 1.7 and 2.9 µg/106 
cells 30 days after treatment with 10 and 30 µM of NM3RPV, respectively. (Figure 3.6.7; 
3.6.9) Conversely, NRPV treatment yielded RPV levels that fell below the limit of 
quantitation within 20 days, with significantly lower drug concentrations at all time points 
when compared against NM3RPV treatment. Importantly, at both doses (10 and 30 µM) 
sustained RPV concentrations were detected for 30 days in NM3RPV-treated cells. To 
examine whether sustained release of drug would protect MDM against HIV-1 infection, 
we challenged cells with HIV-1ADA up to 30 days after drug loading and assayed 
quantitatively for RT activity, as well as qualitatively for HIV-1p24 antigen. Both 10 and 
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30 µM, NM3RPV suppressed HIV-1 RT activity by > 96% at all challenge time points. 
(Figure 3.6.8; 3.6.10) In contrast, treatment of MDM with 10 µM NRPV provided 67% 
reduction of RT activity when challenged 10 days post treatment, with complete viral 
breakthrough occurring at day 20. Similarly, 30 µM NRPV provided only 42% viral 
inhibition at day 30. Therefore, enhanced MDM drug uptake and retention (and 
continued RPV release) exhibited by NM3RPV provides superior protection against HIV-
1 challenge compared with NRPV.  
3.4.4 PK and BD  	  
Prodrug modification not only alters the physicochemical properties of a 
compound, but also can change its pharmacokinetic profile and tissue distribution. 
Therefore, we administered a single IM injection of 45, 75, and 100 mg/kg RPV-eq. 
doses of NM3RPV or NRPV to male BALB/cJ mice. NM3RPV generated lower initial 
plasma RPV concentrations coupled with slower plasma decay kinetics compared with 
NRPV. Specifically, animals dosed with 45, 75, 100 mg/kg NRPV maintained RPV 
plasma concentrations above the PA-IC90 (12 ng/mL) for 4, 6, and 7 weeks before falling 
below the limit of quantitation of 0.5 ng/mL by 10, 13, and 16 weeks. (Figures 3.6.11; 
3.6.14; 3.6.17) In comparison, NM3RPV provided sustained plasma RPV concentrations 
above the PA-IC90 for 4, 12, and 25 weeks at doses of 45, 75, and 100 mg/kg RPV-eq. 
respectively. Furthermore, NM3RPV treated animals exhibited 13- and 26-fold increases 
in t1/2 and MRT compared with NRPV respectively. (Table 3.6.1) Moreover, NM3RPV 
significantly improved tissue biodistribution compared with NRPV. Particularly, NM3RPV 
provided significantly higher RPV concentrations in the spleen, liver, gut, and kidney 8 
weeks following drug administration at all doses (45, 75, and 100 mg/kg). (Figures 
3.6.12; 3.6.15; 3.6.18) Importantly, at the conclusion of the study (46 weeks), RPV 
concentrations were still detectable in most tissue tested (spleen, lymph node, liver, gut, 
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kidney), with a significant tissue distribution observed in the lymph nodes (145 ng/g). By 
comparison, RPV was not found above the limit of quantitation in any tissue collected 46 
weeks after treatment with NRPV. Furthermore, we assayed all tissues for the presence 
of NM3RPV.  Lymph node, spleen, and liver were substantial depots for M3RPV, 
containing 26,941, 674, and 220 ng/g of M3RPV 46 weeks after injection, respectively. 
(Figure 3.6.19)  
Next, to investigate whether species differences in M3RPV cleavage kinetics 
might generate differences in plasma and tissue distribution, NM3RPV was evaluated 
after a single IM injection of 45 mg/kg RPV-eq. in rhesus macaques. (Figure 3.6.20) We 
observed a significant presence of prodrug in plasma, whereby concentrations of 
M3RPV were between 2-16 fold higher than RPV across the course of 44 weeks of 
investigation. Furthermore, rectal, lymph node, adipose biopsies collected 204 days after 
NM3RPV treatment contained measurable levels of both M3RPV and RPV. Specifically, 
RPV concentrations of 8.7, 23.7, and 19.7 ng/g were detected in the rectal, lymph node 
and adipose tissue at day 204. Moreover, M3RPV was distributed and retained in the 
lymph node and adipose tissue (456.3 and 532.3 ng/g), with lower levels detected in 
rectal tissue (7.4 ng/g). 
3.4. NM3RPV PrEP in humanized mice 	  
 To determine the efficacy of NM3RPV against HIV-1 challenge, we employed a 
CD34+ humanized mouse model for PrEP studies. Specifically, animals were given a 
single injection of NM3RPV (100 mg/kg) and subsequently challenged with HIV-1ADA (IP) 
2 weeks after treatment. Plasma viral loads 2 and 4 weeks after challenge revealed 
plasma viral RNA levels similar to untreated controls. (Figure 3.6.21) Furthermore, 
plasma was collected to assay RPV concentrations at the time of viral challenge. 
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Specifically, RPV concentrations were ~2.5 times the PA-IC90 at time of challenge with 
HIV-1ADA. (Figure 3.6.21) 
3.5 Discussion 	  
Treatment of HIV-1 infection requires life-long ART to maintain viral suppression, 
CD4+ T cell numbers and lifespan.2,3 Since inception, ART required strict adherence for 
both treatment of existing infection and for pre-exposure prophylaxis.90 While ART has 
evolved to formulations requiring a single daily pill,94 LA formulations such as injectable 
or implants have received considerable support from large numbers of infected or at risk 
patients.95,96 In sub-Saharan Africa, which bears the largest global burden of HIV-1 
infections, increased use of injections or implants for contraception have laid the 
groundwork for LA ART.58,59  
Monthly administration of CAB and RPV LA has seen levels of viral suppression 
consistent with established oral treatments.28,56,57 Therefore, as LA ART comes closer 
towards approval, optimization of delivery and incorporation of a broader range of ARVs 
are in increasing demand. In parallel, reducing injection volume, dose frequency, 
injection site reactions while increasing tissue drug penetrance remain in want.66 While 
implantable devices can alleviate some of these concerns, cost and access remain 
limitations.60,61,64,84 In effort to improve drug biodistribution and global use, LASER ART 
was created.  It employs a prodrug approach to incorporate ARVs into nanocrystals 
generating sustained plasma drug concentrations with efficient tissue and cell reservoir 
delivery.67,70,71,76  
Our present studies focused on the synthesis, nanoformulation, and 
characterization of a myristoylated RPV (M3RPV). Prodrug modification transiently 
changes the structure of a compound to achieve a specific goal, such as alteration of 
physicochemical or pharmacokinetic properties.69 RPV is a poorly soluble 
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diarylpyrimidine (DAPY) derivative extensively studied as a LA formulation (RPV-LA).37-39 
Previous research has demonstrated that synthesizing hydrophobic prodrugs of 
inherently low solubility compounds can be beneficial, particularly by increasing the 
apparent half-life and/or enhancing tissue distribution. 70,71,97,98 M3RPV was 
manufactured as a LA nanoparticle coined as NM3RPV using high-pressure 
homogenization. For comparison, we best replicated RPV-LA, with the manufacture of 
NRPV. In particular, we used the same surfactant (P338), generating particles of 277 
nm, similar to the 200 nm RPV-LA formulations.37,39 Both preparations use top-down 
approaches for manufacture.37,39  
Stability is important for clinical translation. NM3RPV demonstrated exceptional 
physicochemical stability at 4° and 37°C over a period of 100 days. Furthermore, 
injectable formulations must provide repeatable PK results months after initial 
manufacture. In our studies, NM3RPV provided congruent RPV concentrations in mice 
plasma after injection with both new and aged formulations. Drug delivery to viral 
reservoirs remains a challenge.99,100 LA injectable formulations are designed to generate 
slow dissolution depots at the injection site. Furthermore, infiltrating macrophages have 
been observed sequestering nanocrystals at the injection site facilitating their 
biodistribution.71,101 These cells are phagocytic and highly mobile.102 In particular, 
macrophages have large cytoplasmic volumes, such that phagocytized drug 
nanocrystals can be stored extended time periods.67,70,103 Therefore, nanocrystals can 
develop a cell based tissue depot, but also more efficiently deliver drug to sites of viral 
infection. Prodrug modifications, particularly those that increase lipophilicity, have been 
observed to increase macrophage drug uptake and retention.70,71,75,76 In our work, 
NM3RPV and NRPV both readily enter macrophages, but only NM3RPV is retained for a 
significant period of time, indicating that NM3RPV may establish a secondary tissue 
depot for RPV. 
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 Prodrug modification not only significantly alters a compound’s physicochemical 
properties, but also its pharmacokinetics and biodistribution.104 In our studies, NM3RPV 
generated substantial differences in the duration of plasma exposure, as well as tissue 
distribution when compared to NRPV. We treated mice with 100 mg/kg RPV-eq. To 
mirror the human equivalent dose administered in clinical trials.28,56 Prodrug modification 
provided a shallow plasma RPV decay curve and sustained RPV concentrations 48 
weeks after injection. Specifically, RPV concentrations were above the proposed PA-IC90 
(12.5 ng/mL) for 25 weeks after administration. These results are significant when 
compared with 7 weeks above the PA-IC90 observed with NRPV. Clinical trials 
demonstrating viral suppression with RPV-LA and CAB-LA injections every 8 weeks 
observed Ctrough RPV concentrations of 64 ng/mL or ~ 5 times the PA-IC90.28 In addition, 
viral breakthrough was observed in a patient after accidental HIV-1 exposure 41 days 
after RPV LA injection (300 mg) exhibiting approximately 10.5 ng/mL RPV in plasma on 
the day of exposure.105 Therefore, future work must focus on increasing RPV plasma 
concentrations to at least the RPV-LA Ctrough by optimizing dosing schedules or affecting 
prodrug structure.  
Furthermore, administration of 45 mg/kg RPV-eq. of NM3RPV to rhesus 
macaques resulted in sustained levels of M3RPV in the plasma over the course of 44 
weeks, but provided low levels of active RPV, which quickly fell below the PA-IC90. We 
observed a similar ratio of M3RPV:RPV in the plasma 24 hours after injection compared 
to our mice studies. Specifically, 24 hours after injection mice and rhesus macaques 
exhibited a M3RPV:RPV ratio of 12.4 and 10.2, respectively. Interestingly 2 weeks later, 
the M3RPV:RPV ratio fell to 0.19 in mice, but remained higher (6.8) in rhesus 
macaques. We hypothesize the stability of M3RPV in monkeys paralleled our plasma in-
vitro cleavage studies where stark differences in prodrug bioconversion were observed 
between species (mouse and rhesus macaque). Observed differences in cleavage 
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kinetics may be due to the lack of abundant carboxylesterases observed in monkey, 
dog, and/or human plasma that are abundant in rodents.106,107 Therefore studies focused 
on the specific mechanism and enzymes responsible for prodrug bioconversion are 
warranted. 
 Impending research directives will investigate formulations of shorter chain RPV 
prodrugs (M1RPV, M2RPV) in rhesus macaques in order to achieve more efficient 
prodrug bioconversion to RPV. LASER-ART employs hydrophobic and lipophilic 
prodrugs to enrich tissue distribution, particularly to sites of viral infection. In our mice 
studies, NM3RPV generated tissue depots in the lymph nodes, spleen, and liver, 
whereby substantial prodrug concentrations were observed 46 weeks after injection 
(26,941, 674, 220 ng/g, respectively). We posit that the prodrug tissue depots, coupled 
with the slow cleavage kinetics of M3RPV, provided sustained RPV concentrations not 
only in the plasma, but in tissues (spleen, lymph node, liver, gut, kidney) where RPV was 
still detectable 46 weeks after treatment. These findings provide significant 
improvements in the long-term distributions of RPV to tissues important in viral 
replication. Importantly, rhesus macaques also retained relevant concentrations of both 
M3RPV and RPV in the lymph nodes 204 days after injection. 
In our studies investigating PrEP in CD34+ humanized mice we did not observe 
any protection from NM3RPV treatment, even with RPV plasma concentrations of more 
than 2x the PA-IC90 a the time of viral challenge. Previous studies investigating RPV LA 
in mice models of HIV-1 infection have produced varying results. Specifically, RPV LA-
dosed bone marrow lymphoid thymus (BLT) mice (300; 600 mg/kg) were challenged 
vaginally with HIV-1CH040 one week after treatment and had successfully suppressed 
virus during the course of study.108 While protection was observed, the treatment dose 
was not clinically relevant was 3-6 times higher than the dose given in our study. 
Additionally, they used a mucosal infection model compared with our IP viral inoculation. 
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Furthermore, studies in humanized CD45+ mice combined 3TC, TDF, and RPV LA to 
successfully suppress virus.109 Moreover, upon viral suppression, animals were 
maintained on RPV LA (160 mg/kg) monotherapy, and viral rebound occurred. These 
studies help to frame our reported PrEP studies in context and understand the 
challenges and limitations of each model system when studying HIV-1 infection in mice. 
In conclusion, LA ART is a significant step forward in the field of HIV-1 
therapeutics. In particular, RPV LA has garnered excitement with its success coupled 
with CAB-LA in phase 3 clinical trials. In our studies, we aimed to generate a LASER-
ART formulation of RPV by generating a series of hydrophobic prodrugs in an attempt to 
increase its tissue distribution and apparent half-life. Our studies provide an excellent 
proof-of-concept that nanoformulated prodrugs of RPV can provide sustained release of 
RPV and the generation of a significant secondary tissue depot. Further work studying 
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3.6 Figures 	  	  
 
Figure 3.6.1 M3RPV Solubility.  	  
(A) Water and (B) 1-octanol solubility of M3RPV and RPV was measured following 24 
hours incubation. Data expressed as mean ± SEM for n=3 replicates (** = P < 0.01, **** 











Figure 3.6.2 M3RPV Cleavage Kinetics.  	  
Plasma cleavage kinetics of M3RPV was tested in various species (mouse, rat, rabbit, monkey, 
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Figure 3.6.3 M3RPV Antiviral Activity.  	  
Antiviral activity of M3RPV and RPV in (A) MDM and (B) CEM-CD4+ T-cells was assessed at a 
range of concentrations (0.1-1000 nm) and determined by RT activity after viral challenge with 
HIV-1ADA (MOI 0.1). Data was normalized and expressed as percentage of HIV-1 control (mean ± 
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Figure 3.6.4 Physicochemical stability NM3RPV and NRPV.  	  
(A-C) Physicochemical stability of NRPV and (D-F) NM3RPV were evaluated for size 
(nm), polydispersity (PDI), and zeta potential (mV) at multiple temperatures (RT, 4, 37°) 
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Figure 3.6.5 Morphology of NM3RPV and NRPV.  	  
Transmission electron microscopy (TEM) provided a morphological assessment of 
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Figure 3.6.6. NM3RPV prodrug stability and PK reproducibility.  	  
(A) Prodrug stability within nanoformulated M3RPV (NM3RPV) was determined by 
analyzing the ratio of M3PRV to RPV in NM3RPV over a period of 100 days. Data 
expressed at mean ± SEM for n=3 measurements. (B) BALB c/J mice were administered 
NM3RPV (45 mg/kg RPV eq.) upon initial manufacture and after 90 days of storage to 
determine the pharmacokinetic reproducibility of NM3RPV. Data are expresses as mean 
+ SEM of n=4 animals. 
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Figure 3.6.7 In-vitro characterization of NM3RPV in human macrophages (10 µM).	  	  
Nanoformulation uptake and retention was assessed in human MDMs. Specifically, 
NM3RPV and NRPV were evaluated for uptake (A) and retention (B) of intracellular RPV 
and M3RPV at a concentration of 10 µM. Data is expressed as mean ± SEM with n=3 
biological replicates (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 as 
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Figure 3.6.8 Long-term antiretroviral efficacy in MDMs (10 µM).  	  
Long-term antiretroviral efficacy of NM3RPV and NRPV was examined after a single 
treatment of 10 µM for 8 hours, followed by HIV-1ADA challenge up to 30 days post 
treatment. Infection was characterized by RT activity (A) and HIV P24 antigen 
expression (B). RT activity data was normalized as a percentage of HIV-1 positive 
control and expressed as mean ± SEM with n=4 biological replicates. Representative 
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Figure 3.6.9 In-vitro characterization of NM3RPV in MDM (30 µM).  	  
Nanoformulation uptake and retention was assessed in MDMs. Specifically, NM3RPV 
and NRPV was evaluated for uptake (A) and retention (B) of intracellular RPV and 
M3RPV at a concentration of 30 µM. Data is expressed as mean ± SEM with n=3 
biological replicates (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 as 
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Figure 3.6.10 Long-term antiretroviral efficacy in MDMs (30 µM).  	  
Long-term antiretroviral efficacy of NM3RPV and NRPV was examined after single 
treatment of 30 µM for 8 hours, followed by HIV-1ADA challenge up to 30 days post 
treatment. Infection was characterized by RT activity (A) and HIV-1 p-24 antigen 
expression (B). RT activity data was normalized as a percentage of HIV-1 positive 
control and expressed as mean ± SEM with n=4 biological replicates. Representative 
images of MDMs stained for HIV-1 p-24 antigen expression are shown. 
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Figure 3.6.11 Murine plasma RPV concentration (45 mg/kg)  	  
Male BALB/cJ mice were administered a single IM injection of NM3RPV or NRPV at 45 
mg/kg RPV-eq. Plasma RPV concentrations were determined by UPLC-MS/MS. Data is 








	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   77	  
 
Figure 3.6.12 Murine RPV tissue distribution (45 mg/kg)  	  
Male BALB/cJ mice were administered a single IM injection of NM3RPV or NRPV at 45 
mg/kg RPV-eq. Tissue biodistribution of RPV was assessed 56 and 323 days after 
injection in the spleen, lymph node, liver, gut and kidney. Data is expressed as mean ± 
SEM for n = 4/5 (**** P < 0.0001, *** P < 0.001, ** P < 0.01, * P < 0.05. # P < 0.1 by 
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Figure 3.6.13 Murine M3RPV tissue distribution (45 mg/kg) 	  
 Male BALB/cJ mice were administered a single IM injection of NM3RPV or NRPV at 45 
RPV-eq. Tissue biodistribution of M3RPV was assessed 56 and 323 days after injection 
in the spleen, lymph node, liver, gut and kidney. Data is expressed as mean ± SEM 
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Figure 3.6.14 Murine plasma RPV concentrations (75 mg/kg)  	  
Male BALB/cJ mice were administered a single IM injection of NM3RPV or NRPV at 75 
mg/kg RPV-eq. Plasma RPV concentrations were determined by UPLC-MS/MS. Data is 
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Figure 3.6.15 Murine RPV tissue distribution (75 mg/kg)  	  
Male BALB/cJ mice were administered a single IM injection of NM3RPV or NRPV at 75 
RPV-eq. Tissue biodistribution of RPV was assessed 56 and 323 days after injection in 
the spleen, lymph node, liver, gut and kidney. Data is expressed as mean ± SEM where 
n ≥ 4 biological replicates (**** P < 0.0001, *** P < 0.001, ** P < 0.01, * P < 0.05. # P < 
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Figure 3.6.16 Murine M3RPV tissue distribution (75 mg/kg)  	  
Male BALB/cJ mice were administered a single IM injection of NM3RPV or NRPV at 75 
RPV-eq. Tissue biodistribution of M3RPV was assessed 56 and 323 days after injection 
in the spleen, lymph node, liver, gut and kidney. Data is expressed as mean ± SEM 
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Figure 3.6.17 Murine plasma RPV concentration (100 mg/kg) 	  
Male BALB/cJ mice were administered a single IM injection of NM3RPV or NRPV at 100 
mg/kg RPV-eq. Plasma RPV concentrations were determined by UPLC-MS/MS. Data is 
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Figure 3.6.18 Murine RPV tissue distribution (100 mg/kg)  	  
Male BALB/cJ mice were administered a single IM injection of NM3RPV or NRPV at 100 
RPV-eq. Tissue biodistribution of RPV was assessed 56 and 323 days after injection in 
the spleen, lymph node, liver, gut and kidney. Data is expressed as mean ± SEM where 
n ≥ 4 biological replicates (**** P < 0.0001, *** P < 0.001, ** P < 0.01, * P < 0.05. # P < 
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Figure 3.6.19 Murine M3RPV tissue distribution (100 mg/kg) 
  
Male BALB/cJ mice were administered a single IM injection of NM3RPV or NRPV at 100 
RPV-eq. Tissue biodistribution of M3RPV was assessed 56 and 323 days after injection 
in the spleen, lymph node, liver, gut and kidney. Data is expressed as mean ± SEM 
where n ≥ 4 biological replicates 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   85	  
 
Figure 3.6.20 Rhesus macaque RPV and M3RPV plasma and tissue distribution. 	  
 Four rhesus macaques were administered 45 mg/kg RPV eq. of NM3RPV by a single 
intramuscular injection. (A) Plasma samples were collected and assayed for RPV and 
NM3RPV throughout the course of study (316 days). Additionally, rectal, lymph node, 
and adipose tissue biopsies were collected 204 days after drug administration. Tissue 
samples were assayed for RPV (B) and NM3RPV (C) content. Both plasma and tissue 
drug concentrations were determined by UPLC-MS/MS. Data is expressed as mean ± 
SEM where n = 4 biological replicates. 
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Figure 3.6.21 NM3RPV humanized mice PrEP study. 	  
CD34+ humanized mice were administered 100 mg/kg RPV eq. NM3RPV and 
subsequently challenged with HIV-1ADA 2 weeks after drug treatment. Animals without 
treatment served as HIV-1+ controls. (A) Plasma viral loads analyzed 2 and 4were 
detected for each condition. (B) Plasma collected from NM3RPV treated animals were 








Table 3.7.1 PK parameters 	  
Non-compartmental PK analysis of NM3RPV and NRPV doses at 45, 75, and 100 mg/kg 











	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   88	  
 
CHAPTER 4 
THE POTENTIAL APPLICATION OF MVC AS A LA 
THERAPUETIC 
 
4.1 Abstract 	  
MVC (MVC; Selzentry) is a well-known CCR5 co-receptor antagonist used as 
part of combination antiretroviral therapy (cART) for HIV-1 infected people with CCR5-
tropic (R5) virus. A twice-daily dosing regimen, low bioavailability, and rapid metabolism 
limit its maximal efficacy. We sought to overcome known limitations of MVC by 
developing a LA parenteral formulation. A variety of formulation techniques ranging from 
polymeric nanoparticles to solid drug nanosuspensions were employed to facilitate 
extended release of MVC. Additionally, prodrugs and hydrophobic salts were generated 
to aid nanoparticle development. Multiple nanoformulations and prodrugs were produced 
for MVC, although a functional LA MVC formulation is still elusive and will require further 
study.  
4.2 Introduction 	  
ART provides sustained suppression of HIV replication, restoration of immune 
function, and reduction in disease morbidity and mortality. Strict life-long adherence is 
required to achieve the effects of ART.  Particularly, in the context of PrEP, adherence is 
essential as drug concentrations strongly correlate to protection.110 Unfortunately, even 
in clinical setting, adherence is remarkably low.111 Thus, the potential use of LA therapy 
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for PrEP is currently being researched.83 Among prospective drug candidates for LA 
PrEP is maraviroc (MVC). Acting as a CCR5 inhibitor, MVC prevents viral entry of R5 
tropic strains of HIV-1 that are most commonly encountered during infection. 
Furthermore, MVC is readily distributed to vaginal and rectal tissue, and can also be 
found in semen after oral administration.42,43 MVC oral regimens require twice-daily 150-
600 mg doses depending on whether patients are receiving a CYP3A inducer or 
inhibitor.112 Therefore to simplify treatment and generate a better dosage form for PrEP, 
our studies focused on prodrug and hydrophobic salt synthesis for successful 
development of a LA MVC therapy. We successfully synthesized two distinct MVC 
prodrugs (MVC14; MVC-PRO), a hydrophobic salt (MVC-PA), and a multitude of diverse 
nanoformulations. Ultimately, a LA MVC amenable for PrEP remained elusive and will 
require further research. 
4.3 Materials and Methods 
4.3.1 Reagents 	  
Maraviroc (MVC) was a generous gift from ViiV Healthcare (Research Triangle 
Park, NC). Dichloromethane (DCM), tetrahydrofuran (THF), N,N-dimethylformamide 
(DMF), Chloroform, sodium bis(trimethylsilyl) amide (NaHMDS,1 M in THF), hexanes, 
ethyl acetate, dimethyl sulfoxide (DMSO), myristoyl chloride, pamoic acid, zinc chloride 
(ZnCl2), sodium iodide (NaI), deuterated chloroform, celite, tert-Butylmagnesium chloride 
(1.0 M in THF), ciprofloxacin, paraformaldehyde (PFA), 3,3’-diaminobenzidine (DAB) 
and Pluronic F127 (P407) was purchased from Sigma-Aldrich (St. Louis, MO). Heptyl 
chloroformate was purchased from Boc Sciences (Shirley, NY). 1,2-distearoyl-syn-
glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-phospho-(1’rac-glycerol) 
(DSPG), and 1,2-distaroyl-syn-glycero-3-phosphoethanolamine-N-
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[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) were purchased from Avanti Polar 
Lipids, Inc. (Alabaster, AL). Acetonitrile (ACN), methanol (MeOH), cell-culture grade 
water (endotoxin-free), KH2PO4, bovine serum albumin (BSA), Triton X-100, and 
gentamicin were purchased from Fisher Scientific (Hampton, NH). Flash column 
chromatography was performed on 32-63 µm flash silica gels, while thin layer 
chromatography utilized pre-coated silica plates (250 µm, F-254) both from SiliCycle Inc. 
(Quebec, Canada) and Dulbecco’s Modified Eagle Medium (DMEM) were purchased 
from Corning Life Sciences (Tewksbury, MA). Polymer-based HRP-conjugated anti-
mouse Envision+ secondary antibody was purchased from Dako (Carpinteria, CA). 
4.3.2 MVC Hydrophobic salt formation 	  
MVC and pamoic acid (PA) were added to separate glass beakers and stirred in 
water at 40°C to form a suspension. Next, hydrochloric acid (HCL; 3M) was added 
dropwise to the MVC suspension until all MVC was dissolved resulting in a clear 
solution. Furthermore, sodium hydroxide (NaOH; 3M) was added dropwise to the PA 
mixture until complete solubilization yielded a clear yellow liquid. Subsequently, the 
solubilized MVC solution was added to the PA solution in a dropwise manner. Upon 
addition an immediate precipitate formed and the mixture was stirred for an additional 30 
min at RT. Next, the mixture containing MVC:PA salt was centrifuged (10,000 g for 30 
min) and subsequently washed with water. Collected pellets were dried and lyophilized 
to yield a fine yellow powder.  
4.3.3 Manufacture of nanoformulated MVC (nMVC) 
Single emulsion solvent evaporation was used to nanoformulate MVC. 
Specifically, DSPC, DSPE-PEG2000, and DSPG (7:1:0.7 molar ratio) were dissolved in 
chloroform and subsequently evaporated to generate a thin film at the bottom of the 
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glass vial. Samples were dried in a desiccator for a minimum of 2 hours before being 
resuspended with water. Poly(lactic-co-glycolic) acid (PLGA; 75:25) and MVC were 
dissolved in DCM and added to the aqueous solution of hydrated lipids. Next, samples 
were sonicated in an ice bath for 7 minutes followed by rotary evaporation to remove 
organic solvent (DCM). Following evaporation, formulations were centrifuged at 5,000 g 
for 5 min, followed by 10,000 g for 15 min. The resultant pellets were resuspended with 
water and centrifuged at 200 g for 3 min to yield the final nanoformulation. nMVC was 
characterized by dynamic light scattering (DLS, Malvern Nano-ZS, Worcestershire, UK) 
for size (nm), polydispersity (PDI), and zeta potential (mV) and analyzed for drug content 
as described below. 
4.3.4 Synthesis of chloromethyl tetradecanoate 	  
Myristoyl chloride was reacted with 1.0 equivalent (eq.) PFA and 0.025 eq. ZnCl2 
under reflux conditions for up to 16 hours. The reaction mixture was then cooled to RT 
and partitioned between DCM and saturated aqueous sodium bicarbonate in a 
separatory funnel. The aqueous layer was back-extracted twice with DCM. Organic 
extracts were combined, washed with brine and dried from sodium sulfate. The solvents 
were evaporated on a rotary evaporator followed by isolation of the desired compound 
using silica column chromatography eluting with a mobile phase of 9:1 hexanes-ethyl 
acetate.  
4.3.5 Synthesis of iodomethyl tetradecanoate 	  
Chloromethyl tetradecanoate (1 eq.) and NaI (2.5 eq.) were dissolved in a 2:1 
mixture of ACN/DCM under an argon atmosphere. The reaction proceeded for 90 hours 
at RT under light protection. Upon completion, the mixture was concentrated and 
partitioned between DCM and water. The aqueous layer was further extracted with DCM 
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followed by sequential washing of the combined organic extracts with saturated sodium 
bicarbonate and brine. The sample solution was then dried from sodium sulfate, 
concentrated and purified by silica column chromatography eluting with 9:1 hexanes-
ethyl acetate.  
4.3.6 Synthesis of MVC-14 	  
Briefly, NaHMDS (2.0 eq.) was dissolved in anhydrous THF and cooled to 0°C on 
ice. Next, a solution of MVC (1.0 eq.) in THF was slowly added to the reaction mixture 
and allowed to warm to RT over the course of 30 min under argon atmosphere. Next, 
iodomethyl tetradecanoate (3.0 eq.) was added slowly to the reaction over the course of 
5 min. The reaction continued at 60°C under reflux conditions for at least 48 hours. Upon 
completion, the reaction was cooled to 0°C and quenched with saturated NH4Cl. Next, 
the reaction mixture was extracted between DCM and brine. The aqueous layer was 
washed twice with DCM. Afterwards, combined organic layers were washed with water 
and subsequently dried from sodium sulfate and concentrated by rotary evaporation. 
MVC-14 was purified by silica column chromatography using a mobile phase of 9:1 
DCM:MeOH. Purified product was collected, dried, and analyzed by 1H NMR yielding 
brown colored oil. Furthermore, MVC-14 oil was dissolved in MeOH (60°C) and stirred in 
the presence of carbon/10% palladium for 10 min. Next, the sample was filtered through 
celite and dried to yield a sticky solid. Precipitation in hexanes yielded a white solid. 
4.3.7 Synthesis of MVC-PRO 	  
MVC was suspended in anhydrous toluene, evaporated, and dried on a 
lyophilizer for at least 16 hours. Next, MVC was dissolved in anhydrous THF and cooled 
to -78°C in a dry ice/acetone bath under argon atmosphere. Thereafter, tert-butyl 
magnesium chloride (2.0 eq.) was added to the reaction mixture dropwise and mixed for 
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10 min. Heptyl chloroformate (1.1 eq.) was subsequently added dropwise and the 
reaction was allowed to warm to RT over time and ultimately proceeded for a minimum 
of 16 hours. MVC-PRO was purified by silica column chromatography and the isolated 
product analyzed by 1H NMR to confirm chemical modification. 
4.3.8 Nanoformulation of MVC-PA and MVC-PRO 	  
Nanoformulations of MVC-PA (L-MVC-PA; P-MVC-PA) and MVC-PRO (nMVC-
PRO) were manufactured using an Avestin EmulsiFlex-C3 high-pressure homogenizer 
(Ottawa, ON, Canada). Briefly, pre-suspension of L-MVC-PA contained MVC-PA (2% 
w/v), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) (0.1% w/v), and 1,2-disteroyl-
sny-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000 (DSPE-
PEG2000) (0.03% w/v) in water. P-MVC-PA required dispersion of P407 (0.6% w/v), 
DSPE-PEG2000 (0.3% w/v), and MVC-PA (2% w/v) in water. Furthermore, nMVC-PRO 
was manufactured by dispersing P407 (1% w/v) and MVC-PRO (2% w/v) in water. All 
formulations were homogenized at 20,000 psi and characterized by dynamic light 
scattering (DLS, Malvern Nano-ZS, Worcestershire, UK) for size (nm), polydispersity 
(PDI), and zeta potential (mV). L-MVC-PA and P-MVC-PA were purified by tangential 
flow filtration (TFF; Spectrum Laboratories, Inc., CA, USA) using a mPES MidiKros Filter 
Module (cut-off size: 0.2 um; surface area 20 cm2). Suspensions starting at 15 mL were 
concentrated to 3 mL followed by diafiltration with 5 or 10 diavolumes (DV) of water. 
nMVC-PRO was concentrated by centrifugation, whereby homogenized samples were 
centrifuged (10,000 g for 10 min) and the subsequent pellet was resuspened in a 
solution of 0.2% P407. Prodrug or MVC content in the nanoformulations were analyzed 
by UPLC-UV/Vis after dilution in MeOH and centrifugation (14,000 rpm for 10 min) as 
described below. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   94	  
4.3.9 Quantification of MVC and MVC-PRO by UPLC-UV/Vis  	  
Drug concentration was assayed on a Waters ACQUITY ultra performance 
liquid chromatography (UPLC) H-Class system with TUV detector and Empower 3 
software (Milford, MA). MVC and MVC-PRO samples were separated on a 
Phenomenex Kinetex 5 µm C18 column (150 x 4.6 mm) (Torrance, CA). MVC was 
detected at 192 nm, using a mobile phase consisting of 74% 50 mM KH2PO4, pH 3.2, 
and 26% ACN and a flow rate of 1.0 mL/min. MVC-PRO was detected at 250 nm, using 
a mobile phase consisting of 50% 50 mM KH2PO4, pH 3.2, and 50% ACN and a flow 
rate of 1.0 mL/min with an elution time of 7.2 min. Drug content was determined by 
comparing peak areas to peak areas from drug standards (0.05-50 µg/mL). 
4.3.10 Plasma Cleavage Studies 	  
Sprague Dawley rat plasma was used to determine the in vitro bioconversion of 
MVC-PRO to MVC. Specifically, MVC-PRO (dissolved in DMSO) was spiked into rat 
plasma at a concentration of 5 µg/mL. Samples were collected (0, 15, 30, 60 min; 2, 4, 7, 
24 hour; D3, D5, D7) by immediately diluting 100 µL plasma into 1 mL ACN and stored 
at -20°C. For analysis, samples were vortexed for 5 min, followed by centrifugation 
(17,000 g for 10 min). Resultant supernatants were transferred to a new tube and dried 
on a speedvac. Samples were resuspended with 200 µL of MeOH and analyzed for 
MVC and MVC-PRO content by UPLC-UV/Vis. 
4.3.11 Half-maximum effective concentration (EC50) assays 	  
Studies to determine the EC50 of MVC and MVC-PRO in MDMs were 
performed in 96-well plates at a density of 0.15 x 106 cells/well. Specifically, cells 
were treated with 0.1-10,000 nM MVC or MVC-PRO for 2 hours, followed by HIV-1ADA 
challenge at a MOI of 0.1 for 16 hours. Following viral challenge, cells were washed 
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   95	  
with PBS, and given fresh 0.1-10,000 nM drug containing media. Supernatants were 
collected 10 days after challenge and assayed for HIV reverse transcriptase (RT) 
activity.85,86 Replicate cells were fixed with 4% PFA and stained for HIV-1 p24 antigen 
by immunohistochemistry.86 
4.3.12 Macrophage cellular uptake and retention studies 	  
Human monocytes were obtained by leukapheresis from HIV-1/2 seronegative 
donors and subsequently purified by counter-current centrifugal elutriation.92 
Monocytes were grown in culture media containing DMEM (4.5 g/L glucose, L-
glutamine, and sodium pyruvate) supplemented with 10% pooled human serum (heat-
inactivated), 10 µg/mL ciprofloxacin, and 50 µg/mL gentamicin. Additionally, cells 
were maintained at 37°C in a 5% CO2 incubator. Human monocytes were plated in 12, 
24, or 96-well plates at 1.0x106, 0.5x106, or 0.15x106 cells/mL respectively. 
Recombinant human macrophage colony stimulating factor (MCSF, 1000 U/mL) was 
added to culture media for 7 days to facilitate monocyte-derived macrophages 
(MDMs) differentiation and vitality in culture.MDM uptake and retention studies were 
performed in 12-well plates, with each treatment group completed in triplicate. Briefly, 
MDMs were treated with 100 µM MVC, nMVC, nMVC-PRO, L-MVC-PA, or P-MVC-PA 
and cells were collected 1, 2, 4,or  8 hours later. For cellular retention studies, drug 
was removed after 8 hours. Cells were washed with PBS and replenished with fresh 
media. Cellular samples were collected at 1, 5, 10, and 15 days to assay intracellular 
drug concentration. Specifically, MDMs were collected by removing media, washing 2 
times with PBS, and scraping the cells into PBS. Cells were subsequently counted 
using an Invitrogen Countess Automated Cell Counter (Carlsbad, CA). Collected 
MDMs were centrifuged at 956 g for 8 min. Cell pellets were sonicated in 200 µL 
MeOH to extract intracellular drug and subsequently centrifuged at 20,000 g for 10 
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min. Samples were analyzed by UPLC-UV/Vis for intracellular drug content as 
described above. 
4.3.13 Murine Pharmacokinetic Studies 	  
Male BALB/cJ mice (6-8 weeks, Jackson Labs, Bar Harbor, ME) were used for 
all PK studies. Specifically, for studies involving nMVC animals were administered 100 
mg/kg subcutaneous (SC) injection of MVC-HCL or nMVC. Studies with MVC-PA 
proceeded with intramuscular (IM; caudal thigh muscle) injections of 50 mg/kg L-MVC-
PA, P-MVC-PA, or MVC-PA (sesame oil). For studies of MVC-PRO, animals were 
administered 50 mg/kg NMVC-PRO, MVC-HCL, or MVC-PRO (sesame oil) by IM 
injection. For all studies, blood samples were collected by cheek puncture into 
heparinized tubes and centrifuged at 2,000 g for 5 min. Plasma supernatants were 
collected and stored at -80°C until further analysis. Plasma drug concentrations were 
determined by UPLC-MS/MS using a Waters ACQUITY UPLC-Xevo TQ-S micro mass 
spectrometry system (Milford, MA) and an ACQUITY UPLC BEH shield, RP18 (1.7 µm, 
2.1 x 100 mm) column. For analyte separation, a mobile phase consisting of A (7.5 mM 
ammonium acetate in Optima-grade water; pH adjusted to 5 with acetic acid) and B 
(100% ACN) and a flow rate of 0.25 mL/min was used. The mobile phase gradient used 
was as follows: 3 min (70% A/ 30% B), 4.5 min (40% A/ 60% B), 5.5 min (5% A /95% 
B), 6.25 min (70% A /30% B) for a run time totaling 8 min. MRM transitions used for 
MVC  were 514.40>389.2, 514.0>280.0 and  514.0>117.0 and for IDV (the internal 
standard; IS) were 614.4>421.0 and 614.4>97.10. For drug analysis 25 µL of plasma 
was mixed with 1 mL of ice cold ACN and subsequently spiked with 10 µL of IS. 
Samples were vortexed (3 min) and centrifuged (17,000 g for 10 min). Supernatants 
were dried, reconstituted with 50% ACN, and injected for UPLC-MS/MS analysis. 
Plasma standards were extracted at a final concentration of 0.1-1000 ng/ml. 
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4.5 Results 
4.5.1 Characterization of the physicochemical properties of nMVC 	  
Polymeric lipid-coated nanoparticles successfully encapsulating MVC (nMVC) 
were manufactured using single emulsion-solvent evaporation. nMVC had an average 
size of 281 nm. Furthermore, particles exhibited a zeta potential of -37 mV and a PDI of 
0.29. Drug loading, which can be defined as the amount of drug present in a defined 
weight of lyophilized nanoparticle powder ((MVC)/(Total weight of lyophilized powder) x 
100) was assessed by UPLC-UV/Vis. Analysis determined drug loading of nMVC 
nanoparticles to be 6.4 %. 
4.5.2 nMVC MDM uptake and retention 	  
Cell cultures of monocyte-derived macrophages (MDM) were used to assess the 
cellular uptake and retention of nMVC compared to MVC. MDM were treated with 100 
µM nMVC or MVC and intracellular drug levels examined after 1, 2, 4, and 8 hours. 
nMVC demonstrated significantly higher uptake compared with MVC, with intracellular 
MVC concentrations of 2.2 and 0.78 µg/106 respectively (*** P < 0.001). To assess the 
potential for macrophage drug depot development, intracellular MVC was analyzed 1, 2, 
4, 6, 8, and 10 days after initial 8-hour treatment. nMVC treated cells retained detectable 
amounts of MVC for the duration of study (10 days), while MVC treated cells fell below 
the limit of detection (0.05 µg/mL) by day 1. 
4.5.3 nMVC MDM antiretroviral efficacy 	  
To determine if improved MDM intracellular uptake and retention specified 
enhanced antiviral activity, cells were challenged with HIV-1ADA 1, 5, 10, and 15 days 
after drug treatment (nMVC or MVC). Specifically, viral breakthrough was witnessed in 
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cells treated with MVC 1 day after treatment. Conversely, nMVC treated cells exhibited 
95% viral inhibition as measured by RT activity 15 days after treatment. Furthermore, 
HIV p24 antigen expression revealed significant infection in MVC treated cells at all time 
points. nMVC treatment provided substantial protection, whereby a small percentage of 
p24 positive cells can be detected at 10 and 15 days after treatment.  
4.5.4 nMVC PK and BD  	  
 Male BALB/cJ mice were administered a 100 mg/kg (SC) injection of nMVC or 
MVC to determine its plasma PK profile. nMVC treatment generated significantly higher 
MVC plasma concentrations at 8 hours, as well as 1 and 2 days after injection compared 
to MVC treatment (* P < 0.05, *** P < 0.001, ** P < 0.01 respectively). Specifically, 
nMVC treatment resulted in MVC plasma concentrations of 1634, 548.9, and 41.0 ng/mL 
at 8, 24 and 48 hours respectively. Conversely, MVC treated animals had 914.7, 190.5, 
and 7.4 ng/mL in the plasma at the same time points. 
4.5.5 Synthesis and characterization of MVC-14 	  
 MVC was successfully modified with a 14-carbon fatty acid moiety to generate a 
hydrophobic prodrug (MVC-14). 1H NMR confirmed the presence of the attached 
aliphatic chain with signals at 0.84 and 1.24 ppm, representing the protons of the 
terminal methyl group and (R-CH2-R) respectively. Furthermore, mass spectrometry 
analysis confirmed MVC-14 by detecting a compound of the correct molecular weight 
(754 m/z). MVC-14 did not readily form a nanosuspension after testing with an 
assortment of surfactants (P407, P188, P338, Tween 20, Tween 80, TPGS) and was not 
further studied.  
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4.5.6 Manufacture, characterization, and nanoformulation of MVC-PA 	  
MVC and pamoic acid (PA) were co-precipitated to form a hydrophobic salt with 
a proposed interaction between the carboxylic acids of PA and the protonated tropane 
and triazole nitrogen groups of MVC. UPLC-UV/Vis analysis determined MVC-PA 
powder to be 49.6% MVC by weight. Nanoformulations of MVC-PA, were generated 
using a top-down manufacturing process and subsequently concentrated by TFF. 
Specifically, P-MVC-PA had an average particle size of 484 nm, while L-MVC-PA 
particles averaged 548 nm. Nanoformulated MVC-PA (L-MVC-PA; P-MVC-PA) was 
administered to MDM (100 µM) to test intracellular uptake. After 8 hours of treatment, 
cells treated with nanoformulations of MVC-PA generated intracellular drug 
concentrations similar to native MVC. Furthermore, BALB/cJ animals were administered 
50 mg/kg MVC, L-MVC-PA, or P-MVC-PA by a single IM injection. Minimal plasma MVC 
concentrations were observed 24 hours after injection with L-MVC-PA and P-MVC-PA 
(50 mg/kg) respectively (35.5 and 13.2 ng/mL). 
4.5.7 MVC-PRO synthesis, characterization, and nanoformulation  	  
 In further studies, MVC was modified by heptyl chloroformate to generate a 
short-chain carbamate prodrug (MVC-PRO). 1H NMR spectra analysis revealed signals 
at 0.88 and 1.20-1.37 ppm corresponding to the terminal methyl and (R-CH2-R) protons 
respectively. Prodrug modification generated substantial changes in aqueous solubility, 
exhibiting an ~1000-fold reduction (2,600 and 2.4 µg/mL) for MVC and MVC-PRO 
respectively. Additionally, we hypothesized our prodrug modification occurred at the 
secondary amine of MVC. To indirectly test this hypothesis, we performed a pH 
dependent solubility study. MVC has two ionizable nitrogen groups, with a pKa of 3.3 
and 7.7, respectively. Therefore, we should observe a similar solubility curve for both 
MVC and MVC-PRO if those groups remained unmodified. MVC exhibited a clear pH 
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dependent solubility with increased solubility below pH 7 and lower solubility at pH 9 and 
11. MVC-PRO exhibited a similar pattern with solubilities of 131.8, 76.9 and 2.4 µg/mL at 
pH 3, 5, and 7, respectively. Soluble MVC-PRO in samples at pH 9 and 11 was below 
the limit of our detection method (0.05 µg/mL). To further characterize MVC-PRO we 
examined its antiviral activity in MDMs. Specifically, MVC exhibited a low-nanomolar 
EC50 value (4.7 nM) consistent with its high antiviral potency. MVC-PRO displayed 
decreased antiviral activity (EC50 = 96 nM), possibly due to relatively slow cleavage of 
MVC from the carbamate prodrug. Therefore we examined the cleavage kinetics of 
MVC-PRO in rat plasma. MVC-PRO effectively released active MVC, but it proceeded 
slowly over the course of multiple days. Specifically, after 24 hours, 29.5% of MVC-PRO 
remained. Importantly, after 24 hours 74% of possible MVC had been released ensuring 
that active compound could be released from MVC-PRO. Importantly, MVC-PRO was 
nanoformulated (nMVC-PRO) successfully using high-pressure homogenization. In 
particular, nMVC-PRO exhibited an average size of 410 nm and PDI of 0.24.  
4.5.8 In vitro and In vivo characterization of nMVC-PRO 	  
 To determine cellular uptake and retention, MDMs were treated with nMVC-PRO, 
MVC-PRO, or MVC (100 µM). After 8 hours of incubation, MDMs treated with nMVC-
PRO showed a 44-fold increase in intracellular drug levels compared to MVC treatment. 
Additionally, non-formulated MVC-PRO was equally as efficient in terms of intracellular 
drug delivery. MVC was detected at all times points in cells treated with nMVC-PRO and 
MVC-PRO, thus indicating prodrug bioconversion. Next, to test MDM retention cells 
were collected 1,3, 5, 7, and 10 days after an initial 8 hour treatment. Intracellular drug 
concentrations of MVC treated cells quickly fell below the limit of detection after a single 
day. Moreover, both nMVC-PRO and MVC-pro exhibited similar retention patterns with 
precipitous decreases in cellular retention occurring within the first day, eventually falling 
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below the limit of detection by day 5. To understand how nanoformulation uptake and 
retention may affect antiretroviral efficacy, we challenged cells with HIV-1ADA at 1, 3, 5, 7, 
and 10 days after drug loading. Viral breakthrough was observed at all timepoints in 
MDMs treated with MVC. Interestingly, both nMVC-PRO and MVC-PRO provided 78 and 
88% reduction in RT activity 10 days after drug treatment. RT activity data was 
qualitatively supported by p24 antigen staining where robust infection is observed at all 
times points after MVC treatment. Minimal p24 positive cells were observed after nMVC-
PRO and MVC-PRO loading when challenged at 7 and 10 days after treatment, 
corresponding to the results of our RT assays. Furthermore, male BALB/cJ mice were 
administered 50 mg/kg MVC-eq. of nMVC-PRO, MVC-PRO (Seasme oil), MVC, or MVC-
PA (Seasme oil) by IM injection. Plasma MVC concentrations 24 hours after injection 
demonstrated 4.2, 15.9, 90.2, and <1 ng/mL for nMVC-PRO, MVC-PRO, MVC-PA, and 
MVC respectively. Unfortunately, MVC plasma concentrations fell below the limit of 
quantitation (0.5 ng/mL) 3 days after treatment for all groups.   
4.6 Discussion 	  
 MVC, the first and only entry inhibitor approved for HIV-1 treatment, has 
generated significant research interest based upon observations of slow disease 
progression in individuals harboring the Δ32 CCR5 mutant.40 A long-acting formulation of 
MVC would be particularly beneficial in PrEP considering its action early in the viral life 
cycle and the observation that most early infection strains are R5 tropic. Furthermore, 
MVC is present in vaginal and rectal tissue, as well as semen after oral dosing.42,43 
Therefore, our studies aimed to evaluate the potential of MVC as a LA HIV-1 
therapeutic. 
 MVC is moderately soluble in an aqueous environment in part due to its 
ionization at physiological pH. Certainly, its solubility is not as high as most NNRTI 
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compounds, although it is substantially more soluble than CAB and RPV, compounds 
currently under long-acting development. Early attempts at top-down nanoformulation 
were unsuccessful, even after screening numerous commonly used surfactants. Based 
on these observations we transitioned to PLGA-based nanoparticles (nMVC) and 
successfully manufactured particles with an average size of 281 nm. Subsequent studies 
in MDM determined nMVC improved intracellular uptake and provided detectable 
intracellular MVC concentrations 10 days after treatment. Furthermore, nMVC exhibited 
protection against HIV-1 infection, whereby 95% inhibition was observed 15 days after 
treatment. Moreover, in vivo testing in BALB/cJ mice exhibited increased plasma MVC 
concentrations up to 3 days following a single SC injection of nMVC compared with 
MVC. These results offered proof-of concept MVC could not only be nanoformulated 
successfully, but could enhance in vitro antiretroviral efficacy and in vivo PK. Ultimately, 
the in-vivo changes were short-acting and therefore did not represent a truly long-acting 
option for further development. Therefore, we investigated alternative approaches to 
alter the physicochemical properties of MVC and facilitate LA nanoformulation 
development. 
 Prodrug synthesis is an approach often employed to transiently modify the 
physicochemical properties of a compound. In particular hydrophilic molecules such as 
3TC and ABC have been converted into hydrophobic prodrugs and ultimately 
successfully nanoformulated.74-76 Reactive and accessible functional groups are required 
for prodrug synthesis. Therefore, we focused our synthetic schemes on the amide group 
present within MVC. Amides are less reactive than other secondary amines due to the 
electron withdrawing nature of its adjacent carbonyl, resulting in partial double bond 
character due to resonance. A significant amount of time and optimization was required 
to synthesize MVC-14, although subsequent nanoformulation was unsuccessful after 
screening a multitude of surfactants. Further prodrug synthesis generated a carbamate 
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prodrug of MVC-PRO. Carbamates are relatively stable due to the partial double bond 
character formed by its possible resonance structures.113 Therefore to ensure MVC-PRO 
released its active form (MVC), we analyzed prodrug bioconversion in rat plasma. MVC-
PRO readily released MVC over a 5-day period, demonstrating its potential utility in 
subsequent efficacy studies. Subsequent in vitro studies revealed its significant 
intracellular uptake and antiretroviral efficacy. Ultimately, PK studies in BALB/cJ mice 
exhibited detectable concentrations of MVC for only a single day following IM injection. 
These results may be due to rapid metabolism of MVC or the lack of conversion of MVC-
PRO in vivo. Further UPLC-MS/MS method development is required to quantitate 
prodrug concentrations in the plasma and tissue.  
 Next, using olanzapine pamoate (ZYPREXA RELPREVV) as a model, we aimed 
to develop an extended release formulation for MVC by generating a hydrophobic 
pamoate salt (MVC-PA).114 Ultimately, PK studies in BALB/cJ mice determined MVC-PA 
did not extend MVC release, providing minimal concentrations of MVC in the plasma for 
just a single day.  
 Transitioning MVC into a LA therapeutic has been extremely challenging. LA 
solid drug nanoformulations in clinical development have focused on highly potent 
hydrophobic compounds such as CAB and RPV. In comparison MVC possesses higher 
aqueous solubility and requires delivery of large amounts of drug due to its rapid 
metabolism.112,115,116 Furthermore, in conjunction with laborious prodrug synthesis, 
creating a MVC LA formulation remains a significant challenge.  
 Recently the manufacture of MVC solid drug nanoparticles (SDN) resulted in 
detectable MVC concentrations for 10 days after IM injection.117 In particular, the 
terminal half-life (t1/2) increased from 53.2 hours for conventional MVC to 140.7 hours in 
MVC SDN, generating a step towards a LA injectable formation of MVC. Furthermore, 
proof-of-concepts studies incorporating MVC into topical gels were able to prevent HIV 
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infection in a humanized mouse model and SIV infection in rhesus macaques.118,119 
Thus, transitioning MVC into an extended release formulation is challenging, but its 
potential application in PrEP, as well as treating other disease states, such as cancer 























Figure 4.7.1 NMVC macrophage uptake and retention.  	  
NMVC and MVC were evaluated for their MDM intracellular uptake and retention after 
100 µM treatment. Data is expressed as mean ± SEM with n=3 biological replicates (* P 















Figure 4.7.2 Comparison of antiretroviral activity of NMVC and MVC in MDM.  	  
(A) HIV-1p24 antigen expression in MDMs challenged with HIV-1 at 1, 5, 10, and 15 
days after initial 8-hour treatment with 100 µM NMVC or MVC. (B) RT activity was 
determined in medium of cells loaded with NMVC or MVC for 8 hours, then challenged 
with HIV-1ADA 1, 5, 10, and 15 days post treatment. Data represents mean ± SEM for n=3 
biological samples.  
 
 








Figure 4.7.3 Murine pharmacokinetic evaluation of NMVC. 	  
Male BALB/cJ mice were administered a single 100 mg/kg subcutaneous (SC) injection 
of NMVC or MVC. MVC plasma concentrations were evaluated for a period of 5 days 
post treatment. Data is expressed as mean ± SEM for n ≥ 10 biological replicates. (* P < 













Figure 4.7.4 Synthesis of iodomethyl chloroformate and MVC14. 	  
(A) Myristoyl chloride was reacted with PFA and ZnCl2 under reflux conditions to 
generate chloromethyl chloroformate. (B) Chloromethyl chloroformate was reacted with 
NaI to generate Iodomethyl chloroformate. (C) MVC was reacted with iodomethyl 
chloroformate to generate a hydrophobic prodrug of MVC (MVC14). 
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Figure 4.7.5 Chemical characterization of MVC14 	  
(A) MVC was modified to generate methylene ester prodrug (MVC14) with an attached 
14-carbon aliphatic chain. 1H NMR spectra revealed signals at 0.84 and 1.24 ppm 
corresponding to the protons of terminal methyl group and (R-CH2-R) respectively. (B) 
Positive electrospray ionization mass spectrometry (ESI-MS) analysis generated a 

























Figure 4.7.6 Proposed structure of MVC:pamoic acid (MVC-PA) salt 	  
MVC and pamoic acid were co-precipitated to form a hydrophobic salt. The proposed 



























Figure 4.7.7 Development of nanoformulated MVC-PA  	  
(A) Nanoformulations of MVC-PA (L-MVC-PA; P-MVC-PA) were manufactured by high-
pressure homogenization, concentrated by TFF, and characterized by dynamic light 
scattering.  (B) MDM intracellular uptake of MVC, L-MVC-PA, and P-MVC-PA over the 
course of 8 hours of treatment (100 µM). Data is expressed as mean ± SEM in n = 3 
biological replicates. (C) MVC plasma concentrations from BALB/cJ mice given a 50 
mg/kg intramuscular (IM) injection of MVC, L-MVC-PA, or P-MVC-PA. Data is expressed 
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Figure 4.7.8 MVC-PRO chemical characterization  	  
(A) MVC was reacted with heptyl chloroformate in the presence of tert-butylmagnesium 
chloride to generate a carbamate prodrug (MVC-PRO) (B) 1H NMR spectra revealed 
signals at 0.88 and 1.20-1.37 ppm corresponding to the protons of the terminal methyl 









Figure 4.7.8 Antiviral activity of MVC-PRO in MDMs.  	  
The antiviral activities of MVC and MVC-PRO were tested at a range of concentrations 
(0.1-10,000 nM) in MDMs. RT activity was determined after viral challenge with HIV-
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Figure 4.7.9 MVC-PRO plasma bioconversion  	  
Plasma cleavage kinetics of MVC-Pro was tested in rat plasma. Briefly, 5 µg/mL MVC-
Pro was spiked in rat plasma and collected at defined time points. Plasma samples were 
immediately spiked in ACN and stored at -80°C until further processing. Drug analysis 
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Figure 4.7.10 MVC-PRO pH dependent solubility  	  
MVC, MVC-PRO and MVC-PA were incubated in aqueous solutions of varying pH (3, 5, 
7, 9, 11) for solubility analysis. Samples were collected after 24 hours of mixing, 
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Figure 4.7.11 NMVC-PRO Macrophage uptake and retention.  	  
Nanoformulated MVC-PRO (nMVC-PRO) and MVC were evaluated for MDM 
intracellular uptake (A) and retention (B) after 100 µM treatment. Intracellular MVC-PRO 
and MVC concentrations were quantified by UPLC-UV/Vis. Data is expressed as mean ± 
SEM with n=3 biological replicates. 
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Figure 4.7.7 PK characterization of MVC-PRO  	  
Male BALB/cJ mice were administered 50 mg/kg nMVC, MVC-PRO, MVC-PA, or MVC 
by IM injection. Blood was collected for 2 weeks after injection for MVC plasma 




























5.1 Discussion 	  
 Treatment of patients infected with HIV-1 is approaching an inflection point. 
Widespread application of oral ART completely changed the narrative surrounding HIV-1 
infection. Once, an HIV diagnosis meant ostracization and impending death. ART 
enabled infected patients the opportunity to live a longer life, in which they could manage 
HIV-1 as more of a chronic condition, albeit requiring strict adherence to treatment 
protocols. Nevertheless, gaps still exist in HIV-1 therapy. Regions such eastern and 
southern Africa harbor most of the global disease burden with over 19 million individuals 
infected.1 Furthermore, only 51% percent of infected patients are currently virally 
suppressed.121 In order to make significant headway, a paradigm shift must take place. 
Ultimately a LA revolution in HIV-1 therapy may be on the horizon. 
 LA formulations have a number of benefits in the context of HIV-1 therapy. First, 
oral ART is effective when strict adherence is maintained. Since HIV-1 remains 
integrated in the host cells of infected patients even while on ART, viral rebound will 
occur if treatment ceases.122 Furthermore, missed doses can lead to suboptimal drug 
concentrations and facilitate the development of resistance mutations. Thus, HIV-1 
requires a life-long battle and any means by which treatment can be simplified is 
advantageous. LA formulations may provide an opportunity for simplification and 
increased effectiveness.  
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 Furthermore, LA formulations have the potential to significantly impact PrEP and 
its associated patient populations. Oral PrEP is successful across vulnerable populations 
of varying sexes and sexual contact, but its effectiveness is contingent on consistent 
adherence.123 Currently, the World Health Organization (WHO) suggests the 
implementation of PrEP for people at substantial risk of HIV-1 infection (> 3% 
incidence).124 Young African women are particularly vulnerable and carry a 
disproportionate burden of HIV infections.125 Unfortunately, clinical trials with oral PrEP 
in young African women have revealed very poor adherence (< 30%) rendering 
preventative measures ineffective.126,127 LA PrEP measures could substantially impact 
this vulnerable subpopulation by administering LA ART during doctor visits and 
significantly increasing prevention effectiveness.  
 RPV- and CAB LA represent the first generation of HIV-1 LA formulations and 
have primarily been studied as monthly injections for maintenance therapy.28,56 Although, 
early investigations into their application for PrEP have been undertaken.53,128 Despite 
preliminary returns of clinical success, limitations have arisen and need to be addressed 
as HIV LA therapy is advanced. Injection site reactions (ISR) are the most commonly 
reported side effect with RPV and CAB LA (~97%) and may be due to the large dosage 
volumes that are necessary for delivery.28,129 Furthermore, there are concerns regarding 
potential toxicity and/or unwanted side effects from treatment, which would be 
irreversible upon injection. Therefore, oral lead-in therapy to determine drug safety and 
tolerance may be necessary. Additionally, discontinuation of therapy is more complex in 
LA treatments. Whereas oral therapy discontinuation would generate precipitous drops 
in plasma drug concentrations, missing a LA injection or ceasing treatment would 
generate a long tail of suboptimal drug concentrations, leading to the potential rise in 
resistance mutations.  
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 LA implants provide an alternative to injectable formulations for HIV-1 treatment 
and prevention. Slow drug release and sustained plasma drug concentration are the 
hallmark of LA implants and are well suited for PrEP. Additionally, a broad range of 
ARVs have been incorporated into implantable devices, unlike injectable forms which 
are limited to those with low solubility. Implants would improve PrEP adherence, but 
often require more advanced technical procedures than a simple injection for insertion 
and removal. Therefore, biodegradable implants delivered by subcutaneous injection are 
particularly attractive. Moreover, implants delivering a single ARV may not be sufficient, 
thus may require insertion of multiple implants or development of multi-drug sustained 
release devices. Lastly, implantable devices do not readily improve drug distribution to 
viral reservoirs, whereas observed macrophage infiltration in the muscle following LA 
injections may be advantageous for tissue delivery.  
 Working towards the next generation in HIV-1 therapy, our lab has developed a 
LA delivery approach deemed LASER-ART. Specifically, LASER-ART utilizes prodrug 
modification of existing ARVs to enhance nanoformulation entry into tissue and cellular 
reservoirs and provide sustained release of efficacious drug concentrations to the 
plasma and sites of viral infection. Furthermore, combining LASER-ART with novel 
CRISPR technologies targeting integrated HIV-1 proviral DNA provided viral elimination 
in a subset of humanized mice.130 Together, these observations led us to develop a 
library of RPV prodrugs with the goal extending the apparent half-life and tissue 
distribution of RPV LA.  
 Four RPV prodrugs were successfully synthesized with varying carbon chain 
lengths (7,12,14,18). M3RPV, our 14-carbon modified prodrug was selected as the lead 
compound. In vitro studies determined delivery of nanoformulated M3RPV facilitated 
improved cellular drug retention and antiretroviral efficacy. These results suggested 
NM3RPV could provide a significant tissue depot in-vivo. Moreover, PK studies in 
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BALB/cJ mice demonstrated prodrug modification could significantly alter terminal half-
life, MRT, and biodistribution. Specifically, NM3RPV generated 13 and 26-fold increases 
in t1/2 and MRT respectively compared with NRPV. Additionally, NM3RPV exhibited 
plasma concentrations above the PA-IC90 for 25 weeks compared with 7 weeks for 
NRPV. Moreover, both prodrug (M3RPV) and active compound (RPV) were detected in 
the spleen, lymph node, and liver 323 days after initial treatment.  
 NM3RPV provided extended RPV release into the plasma, but absolute levels 
did not reach the Ctrough concentrations observed for RPV-LA in clinical trials. It is 
necessary to continue to optimize our delivery mechanism to allow higher plasma 
exposure. Additionally, when we tested NM3RPV in rhesus macaques, plasma RPV 
concentrations rapidly declined. We witnessed extended release of the prodrug 
(M3RPV) in monkey plasma, a finding starkly different from our studies in mice. 
Interestingly, we did observe detectable levels of both RPV and M3RPV in tissue 
biopsies collected from lymph node, adipose tissue, and rectal tissue 204 days after 
injection. These results demonstrate further research is necessary to elucidate the 
reasons for the observed species differences and what measures can be taken to 
address these concerns. Furthermore, it could be reasonable to test some of the shorter-
chain prodrugs in higher species to observe if they can release RPV in a more efficient 
manner than M3RPV. 
 Our presented research provides a proof-of-concept for RPV prodrug 
modification and its effects on PK and BD. As LA HIV injectable formulations become 
available for prevention and maintenance, new alternatives must be developed. LA 
ARVs largest impact will be for PrEP in vulnerable populations, particularly young 
African women. Therefore, research aimed towards making LA ARVs more efficient and 
user friendly will ultimately derive the greatest impact. Transitioning LA treatments from 
once a month to a quarterly or bi-annual schedule, if achieved would be substantial. Bi-
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annual dosing provides the option of mass-drug administration to highly vulnerable 
populations, similar to what is done in Africa for other highly endemic diseases. 
Therefore, our work provides a small step towards this goal. Ultimate realization will 
require the development of novel compounds. Current LA formulations use existing 
ARVs originally developed for oral therapy. Therefore, future compounds will need to be 
highly potent, possess a long inherent half-life, and be specifically designed for LA 
formulation. Furthermore, optimizations such as prodrug modification, nanoformulation 
design, and/or novel implantable devices may be required to achieve extended 
sustained release and tissue distribution requisite for bi-annual therapy. 
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